Accepted Manuscript

Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1-enyl)piperidine and -pyrrolidine with chloropyruvates for the efficient synthesis of substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives

Vakhid A. Mamedov, Elena A. Hafizova, Anastasiya I. Zamaletdinova, Il'dar Kh. Rizvanov, Alla B. Mirgorodskaya, Lucia Ya. Zakharova, Shamil K. Latypov, Oleg G. Sinyashin

PII: S0040-4020(15)30105-8

DOI: 10.1016/j.tet.2015.10.004

Reference: TET 27176

To appear in: Tetrahedron

Received Date: 28 July 2015

Revised Date: 18 September 2015

Accepted Date: 1 October 2015

Please cite this article as: Mamedov VA, Hafizova EA, Zamaletdinova AI, Rizvanov I'dK, Mirgorodskaya AB, Zakharova LY, Latypov SK, Sinyashin OG, Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1-enyl)-piperidine and -pyrrolidine with chloropyruvates for the efficient synthesis of substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives, *Tetrahedron* (2015), doi: 10.1016/j.tet.2015.10.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1enyl)-piperidine and -pyrrolidine with chloropyruvates for the efficient synthesis of substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives

Vakhid A. Mamedov,^{a,b,*} Elena A.Hafizova,^{a,b} Anastasiya I. Zamaletdinova,^{a,b} Il'dar Kh. Rizvanov,^a Alla B. Mirgorodskaya,^{a,b} Lucia Ya. Zakharova,^{a,b} Shamil K. Latypov,^a Oleg G. Sinyashin^{a,b}

> ^aA. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center of the Russian Academy of Sciences, Arbuzov str. 8, 420088 Kazan, Russian Federation

^bKazan National Research Technological University, Karl Marx str. 68, 420015 Kazan, Russian Federation

mamedov@iopc.ru


ABSTRACT: Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1-enyl)piperidine and -pyrrolidine with chloropyruvates has been accomplished for the synthesis of various polysubstituted 4,5,6,7-tetrahydroindoles. This one-pot, general and highly regioselective method avoids harsh conditions and expensive catalysts. It proceeds with high atom-efficiency and shows a broad substrate scope and functional group tolerance, making it a highly practical approach for the preparation of various tetrahydroindole derivatives. A family of 17 tetrahydroindoles was synthesized in good yields, which is indicative of the general character of this reaction. Ten of the tetrahydroindole derivatives with various substituents were successfully transformed into the corresponding indoles. This methodology allows access to indoles bearing ω -halo- (mostly chloro-)butyl and pentyl substituents at the nitrogen atom (by variation of enamines) and at the C2, C3 positions (by variation of pyruvates, including bromoaryl and chloroalkyl derivatives). The reaction can be used in conjunction with enamine synthesis offering a practical three-component heteroannulation methodology to produce 4,5,6,7-tetrahydroindoles from cyclohexanone, pyrrolidine and arylchloropyruvates.

KEYWORDS: Synthetic methods; Enamines; Chloropyruvates; Ring cleavage; 4,5,6,7-Tetrahydro-1H-indoles

INTRODUCTION

Recent studies on the chemistry of indole derivatives have focused on the development of efficient and convenient methods for the synthesis of natural products and their analogues possessing potent biological and physiological activities.¹ One of the urgent directions in this field is the creation of new pathways leading to substances possessing the 4,5,6,7-tetrahydro-1H-indole scaffold. This structural motif is present in two members (Tuberostemonine, Stenine) of the Stemona alkaloid family² and in two members (Lysergic acid, Isolysergic acid) of the ergot alkaloid family.³ Besides, tetrahydroindole derivatives display a wide spectrum of biological activities: anti-implantation, hypoglycemic, antiinflammatory, and analgesic;⁴ potent neuroleptic⁵ (e.g., molindone); and antitumor.⁶ Tetrahydroindoles are also valuable intermediates in the synthesis of natural alkaloids⁷ such as goniomitine, arcyriacyanin A, 6,7-secoagroclavine, and chuangxinmycin, as well as synthetic drugs⁸ (pindolol) and highly functionalized indoles.⁹ The great majority of procedures employed in construction of both Nsubstituted and N-unnsubstituted tetrahydroindoles are based on metal-catalyzed cyclization strategies.¹⁰ However, the synthesis of highly functionalized pyrroles remains challenging and often requires multiple steps or harsh reaction conditions. Here the course of our ongoing research toward the synthesis of heterocycles via Darzens condensation products,¹¹ we describe a novel approach to the synthesis of 2,3-fused pyrroles, mainly 1,2,3-substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives, via the sequential substitution/ring cleavage/addition reaction of commercially available 1-(cyclohex-1envl)-piperidines and 1-(cyclohex-1-envl)-pyrrolidine with arylchloropyruvates, which are readily derived from methyl dichloroacetate and corresponding aldehydes under Darzens condensation (eq 1). We further extend this methodology to the formation of substituted indoles from 4,5,6,7-tetrahydro-1*H*-indoles.

On the basis of the new ring formation in the reactions of 1-cyclohexenylpyrrolidine 1 with arylchloropyruvates 2 we have recently developed a highly efficient and one-step versatile method for the synthesis of 4,5,6,7-tetrahydro-2-phenyl-1*H*-indole derivatives **3** bearing a 1-chlorobutyl substituent at the nitrogen atom.¹² It is based on cascade conversions involving: (a) an intramolecular nucleophilic substitution of the $S_N 2$ type with the formation of an epoxide ring and elimination of Cl, (b) the opening of the pyrrolidine ring in A on exposure to Cl, (c) imino-enamine tautomerism $\mathbf{B} \rightleftharpoons \mathbf{C}$, (d) the opening of the epoxide ring with a concomitant formation of the new pyrrole ring, **D**, and (e) the elimination of water leading to the formation of tetrahydroindole derivatives **3** (Scheme 1), previously reported by us.¹² According to this procedure, we obtained 1-(4-chlorobutyl)-2-(4-aryl)-3methoxycarbonyl-4,5,6,7-tetrahydroindoles (3, 8 examples) in 72-90% yields (Scheme 1).



Scheme 1. Our previous work.


RESULTS AND DISCUSSION

We have suggested that this procedure could be applied to the synthesis of N-alkyltetrahydroindoles 5 (Table 1) and functionalized indoles 10 (Table 2). With this idea in mind, in order to identify the optimal reaction conditions 1-cyclohexenylpiperidine 4a and methyl phenylchloropyruvate 2a were chosen as the test substrates and parameters including the solvent, temperature, and molar ratio of the reagent and substrate were examined in detail. Among the solvents investigated which included ethanol, acetonitrile, dichloromethane, and dioxane, the best result in terms of yield was obtained with dioxane. The reaction was also tried at different temperatures. At room temperature, the reaction of 1cyclohexenylpiperidine 4a and methyl phenylchloropyruvate 2a, depending on the reaction time gave a corresponding 4,5,6,7-tetrahydroindole derivative 5a, piperidinium chloride 6a and unchanged starting substrates as a mixture. When the ratio of substrates differs than 1:1, the yield of piperidinium chloride **6a** as a by product increased. Surprisingly, raising the temperature led to the formation of the 4,5,6,7-tetrahydroindole derivative 5a, almost as a sole product in a 64% yield. However, a trace amount of piperidinium chloride 6a was also obtained. The formation of 6a, might occur through a piperidinium intermediate type of A, as a result of hydrolysis with the formation of piperidine and its hydro chlorination. The highest yield (98%) of product 5a was obtained at reflux temperature with the ratio of substrates 1:1 for 2 h.

The scope of this protocol was then investigated under optimized reaction conditions. Substituted 3-arylhalogenopyruvates **2a-j** were subjected to the reaction with 1-(cyclohex-1-enyl)-piperidine **4a** under metal-free conditions in dioxane under reflux conditions (Table 1). In the cases of substrates with halogen atoms in the aryl group of **2** the yields of the desired products depend on the positions of atoms in the Periodic Table. The higher the position of the atom in the group, the higher the yields of 4,5,6,7-tetrahydroindole derivatives **5** and vice-versa, the lower the position of the atom in the group, the lower the yields of compounds **5**. The substrate with an electron-donating group led to decreased reaction rates (entry 11). This can be rationalized by considering the fact that these groups decrease the positive charge at the C-3 carbon atom bearing a chlorine atom. The presence of stronger electron-donating groups led to even longer reaction times. In contrast, an electron-withdrawing group (entries 7,8,9,10) accelerated the reaction. The reactions proceed successfully wiht both 1-(4-*tert*-butylcyclohex-1-enyl)-piperidine (entry 9) as an enamine component and methyl 3-bromo-2-oxo-3-phenylpropanoate as a ketone component (entry 10). This affords the corresponding products in good yields (Table 1). On the whole, substrates with an electron-withdrawing functional group formed better yields (Table 1, entries 7,8,9,10) than the electron-donating ones (Table 2, entries 5,11).

Table 1

Synthesis of methyl 1-(5-halopentyl)-2-aryl-4,5,6,7-tetrahydroindole-3-carboxylates 5




| Entry | 2 | R ² | R ³ | Hal | 4 | R ¹ | \mathbf{R}_{f}^{a} | Products5:6,yields, % |
|-------|----|--|-----------------|-----|------------|----------------|----------------------|-----------------------|
| 1 | 2a | C ₆ H ₅ | CH ₃ | Cl | 4 a | Н | 0.53 | 5a:6a 95:1 |
| 2 | 2b | C ₆ H ₄ Cl-4 | CH ₃ | Cl | 4 a | Н | 0.51 | 5b:6a 75:12 |
| 3 | 2c | C ₆ H ₄ Br-4 | CH ₃ | Cl | 4 a | Н | 0.73 | 5c:6a 71:20 |
| 4 | 2d | C ₆ H ₄ F-4 | CH ₃ | Cl | 4 a | Н | 0.59 | 5d:6a 68:12 |
| 5 | 2e | C ₆ H ₄ I-4 | CH ₃ | Cl | 4 a | Н | 0.59 | 5e:6a 63:22 |
| 6 | 2f | C ₆ H ₄ Br-3 | CH ₃ | Cl | 4 a | Н | 0.53 | 5f:6a 76:18 |
| 7 | 2g | C ₆ H ₄ NO ₂ -4 | CH ₃ | Cl | 4 a | Н | 0.46 | 5g:6a 76:14 |
| 8 | 2h | C ₆ H ₄ NO ₂ -3 | CH ₃ | Cl | 4 a | Н | 0.48 | 5h:6a 80:15 |

| ACCEPTED MANUSCRIPT | | | | | | | | |
|---------------------|----|-----------------------------------|-------------------------------|----|------------|--------------|------|--------------------|
| 9 | 2d | C ₆ H ₄ F-4 | CH ₃ | Cl | 4 b | <i>t</i> -Bu | 0.53 | 5i:6a 82:11 |
| 10 | 2j | C_6H_4F-4 | C ₂ H ₅ | Br | 4 a | Η | 0.61 | 5j:6b 78:12 |
| 11 | 2k | C ₆ H ₁₃ | CH ₃ | Cl | 4 a | Н | 0.60 | 5k:6a 68:14 |
| 12 | 2a | C ₆ H ₅ | CH ₃ | Cl | 4 b | <i>t</i> -Bu | 0.60 | 51:6a 79:15 |
| 13 | 2m | C ₆ H ₅ | C_2H_5 | Br | 4 a | Н | 0.50 | 5m:6b 66:22 |


^{*a*}eluent 1:2=EtOAc:hexane

The mechanism of the formation of tetrhydroindole derivatives **5** in these reactions is clearly, similar to the mechanism of the formation of 4,5,6,7-tetrahydroindoles **3** in the reactions of 1-(1-pyrrolidino)cyclohexane **1** with arylchloropyruvates **2**.

As can be seen from the data shown in the table, the yield of the desired products for the most cases do not exceed 80% regardless of the nature of the substituent in the phenyl ring of the pyruvate derivative. To clear up the reasons above, in four cases, namely in the cases of the reactions of pyruvates 2a,g and enamine 4a, we have carefully analyzed the reaction mixture and found that in addition to the main products 5a,g and the hydrochloride of piperidine 6a, 2-aryl-1-(piperidin-1-yl)ethanones 7a,b were formed as by-products.




Although the mechanism of the formation of the products 7a, b is but not as yet fully clear, we assume that under the reaction conditions there can occur side reactions involving single-electron transfer, and the formation of the products 7 can be presented as follows.



Scheme 2. Plausible mechanism of the formation of 2-aryl-1-(piperidin-1-yl)ethanones 7.

The analysis of reaction mixtures shows that the expected products of the Stork reaction, i.e. methyl 3-aryl-2-oxo-3-(2-oxocyclohexyl)propanoates **8** or possible products of their further transformation – methyl 3-aryl-4,5,6,7-tetrahydrobenzofuran-2-carboxylates **9** – are not formed.



The structures of all compounds were established unambiguously by various 1D/2D NMR correlation methods.¹³ For example, for **5k** first the proton spin systems of indole (Ind), substituents at N_1 and C_2 fragments were revealed from 1D TOCSY experiments (SI). Then, a whole structure of these moieties were established by combination of ¹H-¹³C HSQC/HMBC correlations. Finally these structural fragments were "bonded" in a single whole according to ¹H-¹³C/¹H-¹⁵N HMBC connectivities (Figure 1). In addition, a number of NOEs strongly supports these structural hypotheses.




Figure 1. ¹H NMR spectra, structure of **5**k with principal NMR correlations ($^{1}H^{-13}C$ and $^{1}H^{-15}N$ HMBC - black arrow, NOEs - blue arrow).


Assuming that enamines 4a,b can be generated from the corresponding cyclohexanone derivative and piperidine, we tried to synthesize 4,5,6,7-tetrahydroindoles 5 in a three-component system "piperidine – cyclohexanone – arylchloropyruvate" in boiling dioxane. Regardless of the order of mixing the reagents and temperature conditions of the reaction, the desired products have not been

7

obtained, apparently due to a set of competing processes. However, the replacement of piperidine on pyrrolidine in the three-component system dramatically affects the result. The 4,5,6,7-tetrahydroindole derivatives **3** with chlorobutyl substituents in position 1 are formed with almost quantitative yields. Indeed, a test reaction between pyrrolidine and cyclohexanone in benzene, rapidly produced enamine **4a**, which underwent a sequential substitution/ring cleavage/addition reaction with arylchloropyruvate **2a** to give 4,5,6,7-tetrahydroindole **3a** with high yield (Table 2). Several arylchloropyruvates with phenyl and *para*-substituted phenyl groups **2a-d** tested reacted with similar facility, affording the corresponding products **3a-d** with high isolated yields. Further studies of the scope of this novel three-component heteroannulation reaction are underway in our laboratory.

Table 2

Synthesis of methyl 1-(5-halopentyl)-2-aryl-4,5,6,7-tetrahydroindole-3-carboxylates **3** under the threecomponent "pyrrolidine – cyclohexanone – arylchloropyruvate" system




| N⁰ | 2 | R | \mathbf{R}_{f}^{a} | Yield 3 , % |
|----|----|------------------------------------|----------------------|--------------------|
| 1 | 2a | C ₆ H ₅ | 0.53 | 3a , 98 |
| 2 | 2b | C ₆ H ₄ Cl-4 | 0.51 | 3b , 82 |
| 3 | 2c | C ₆ H ₄ Br-4 | 0.73 | 3c , 88 |
| 4 | 2d | C_6H_4F-4 | 0.59 | 3d , 92 |

| ^a eluent 1:2=EtOAc:hexane | e |
|--------------------------------------|---|
|--------------------------------------|---|

Having obtained 4,5,6,7-tetrahydroindole derivatives **3** and **5** the next stage was the synthesis of the indole derivatives **10**. Dehydrogenation of **3,5** with the use of chloranil (in boiling *p*-xylene, 17 h) resulted in compounds **10** in good to high yields (Table 2).

Table 2

Synthesis of functionalized indole derivatives **10** from methyl 1-[5-halobutyl(and halopentyl)]-2-aryl-4,5,6,7-tetrahydroindole-3-carboxylates **3** and **5**



8

| N⁰ | 3 or 5 | \mathbf{R}^1 | R^2 | R | n | \mathbf{R}_{f}^{a} | 10, % |
|----|------------|-----------------|-------|--------------|---|----------------------|-----------------|
| 1 | 3 a | Н | Н | Н | 4 | 0.40 | 10a (85) |
| 2 | 3c | Br | Н | Н | 4 | 0.63 | 10c (82) |
| 3 | 3d | F | Н | Н | 4 | 0.51 | 10d (86) |
| 4 | 3g | NO ₂ | Н | Н | 4 | 0.50 | 10g (92) |
| 5 | 5b | Cl | Н | Н | 5 | 0.56 | 11b (71) |
| 6 | 5c | Br | Н | Н | 5 | 0.58 | 11c (69) |
| 7 | 5d | F | Н | Н | 5 | 0.56 | 11d (75) |
| 8 | 5f | Н | Br | Н | 5 | 0.51 | 11f (66) |
| 9 | 5g | NO ₂ | Н | Н | 5 | 0.48 | 11g (90) |
| 10 | 5i | F | Н | <i>t</i> -Bu | 5 | 0.58 | 11i (78) |

^{*a*}eluent 1:2=EtOAc:hexane

CONCLUSIONS

We have developed a convenient and general approach to polysubstituted 4,5,6,7-tetrahydroindoles via the sequential substitution/ring cleavage/addition reaction between 1-cyclohexenylpiperidines and 1-cyclohexenylpyrrolidine and pyruvates. This reaction was successfully combined with the enamine synthesis, which led to the development of an efficient sequential three-component heteroannulation methodology for the construction of the methyl 1-(4-chlorobutyl)-2-aryl-4,5,6,7-tetrahydro-1*H*-indole-3-carboxylates. Dehydrogenation of 4,5,6,7-tetrahydroindole derivatives with chloranil provides an easy access to the poly-functionalized indole scaffold. Studies aimed at the extension of this reaction to other heterocycles are presently underway in our laboratory.

EXPERIMENTAL SECTION

4. Experimental

4.1. General


All NMR experiments were performed with 600, 500 and 400 MHz (600, 500 and 400 MHz for 1 H NMR; 470 and 376 MHz for 19 F NMR; 150, 125 and 100 MHz for 13 C NMR; 60 and 50.7 MHz for

¹⁵N NMR, respectively) spectrometers equipped with a 5 mm diameter gradient inverse broad band probehead and a pulsed gradient unit capable of producing magnetic field pulse gradients in the zdirection of 53.5 G·cm⁻¹. NMR experiments were carried out at 303 K. DPFGROE¹⁴ and TOCSY spectra were obtained using a Hermite-shaped pulse for selective excitation. Chemical shifts (δ in ppm) are referenced to the solvents (CDCl₃ (δ = 7.27 ppm for ¹H and 77.0 ppm for ¹³C NMR) or DMSO-*d*₆ (δ = 2.49 ppm for ¹H and 39.5 ppm for ¹³C NMR), to external CD₃NO₂ (380.2 ppm) for ¹⁵N NMR spectra (conversion factor to NH₃: -380.2 ppm) and to external C₆F₆ (-164.9 ppm) for ¹⁹F NMR spectra. The melting points were determined on a Boetius hot-stage apparatus and are uncorrected. Infrared (IR) spectra were recorded on a Bruker Vector-22 spectrometer. Mass spectra of MALDI were measured on a Bruker mass spectrometer UltraFlex III TOF/TOF. As the matrices 2,5dihydroxybenzoic acid and *para*-nitroaniline were used. For the accurate mass measuring PEG-400 was used. The insertion of the sample was performed with direct injection combined with a water cooling system. The elemental analyses were carried out at the microanalysis laboratory of the Arbuzov Institute of Organic and Physical Chemistry, Russian Academy of Sciences. All solvents were of regent grade and were dried and distilled before use.

4.2. Preparation of 3-chloro(or bromo)-2-oxo-3-arylpropanoates 2

The starting compounds 2a,^{11a} 2b,^{11b} 2c,^{11c} 2d,^{11d} 2f,^{11e} 2g,^{11b} 2h,^{11f} 2k,^{11g} and 2m,^{11a} were prepared according to the published procedures.

Methyl 3-chloro-3-(4-iodophenyl)-2-oxopropanoate (2e) was prepared from methyl 2,2dichloroacetate and *p*-iodobenzaldehyde in toluene using the method described for the synthesis of 2m.^{11b} Yellow oil; yield (72%) 2e; v_{max} (thin film) 1738, 1590, 1489, 1440, 1245, 1165, 856, 750 cm⁻¹. $\delta_{\rm H}$ (400 MHz, CDCl₃) 3.84 (3 H, s, OCH₃), 6.08 (1 H, s, CH), 7.15 (2 H, d, *J* 8.4 Hz, H3,5-Ar), 7.73 (2 H, d, *J* 8.4 Hz, H2,6-Ar).




Ethyl 3-bromo-3-(4-fluorophenyl)-2-oxopropanoate (**2j**) was prepared from ethyl 2,2dibromoacetate and *p*-fluorobenzaldehyde in toluene using the method described for the synthesis of **2m**.^{11b} Yellow oil; yield 2.17 g (85%) **2j**; v_{max} (thin film) 1736, 1605, 1510, 1300, 1231, 1160, 1055, 856, 839 cm⁻¹. δ_H (500 MHz, CDCl₃) 1.33 (3 H, t, *J* 7.1 Hz, OCH₂CH₃), 4.33 (2 H, q, *J* 7.1 Hz, OCH₂CH₃), 6.19 (1 H, s, CH), 7.06 (2H, dd, *J*_{HH} 8.6 Hz, *J*_{HF} 8.6 Hz, H2,6-Ar), 7.45 (2 H, dd, *J*_{HH} 8.6 Hz, *J*_{HF} 3.3 Hz, H3,5-Ar).

4.3. General procedure for the synthesis of 5.

A mixture of alkyl 3-chloro(or bromo)-2-oxo-3-arylpropanoate **1** (3.0 mmol), 1cyclohexenylpiperidine (or 4-*tert*-butyl-1-cyclohexenylpiperidine) 4a(b) (5.2 mmol) and dioxane (30 mL) was heated at reflux for 2 h. After cooling down to room temperature, the precipitate was filtered and recrystallized in toluene (or washed with *i*-PrOH) to give piperidinium chloride (or bromide) **6**. The solvent was removed to give a slightly brown crude product **5**, which was purified on column chromatography with silica gel (eluent – hexane/EtOAc).


Methyl 1-(5-chloropentyl)-2-phenyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5a.



Colorless oil; yield 1.03 g, 95% (**5a**); 3.7 mg, 1% (**6a**); R_f (hexane/EtOAc 2:1) 0.53; [Found: C, 69.9; H, 7.3; N, 3.8. $C_{21}H_{26}CINO_2$ requires C, 70.08; H, 7.28; Cl, 9.85; N, 3.89]. v_{max} (thin film) 3061, 3026, 2937, 2853, 1697, 1606, 1580, 1525, 1481, 1443, 1407, 1373, 1331, 1270, 1238, 1204, 1154, 1121, 1091, 1053, 1025, 963, 919, 845, 825, 786, 763, 733, 703, 648, 612, 516 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_{H} 1.21-1.27 (2 H, m, CH₂-Alk3), 1.46-1.52 (2 H, m, CH₂-Alk2), 1.54-1.60 (2 H, m, CH₂-Alk4), 1.80-1.81 (2 H, m, CH₂-Ind5), 1.87-1.88 (2 H, m, CH₂-Ind6), 2.56-2.59 (2 H, m, CH₂-Ind7), 2.79-2.82 (2 H, m, CH₂-Ind4), 3.38 (2 H, t, *J* 6.6 Hz, CH₂-Alk5), 3.57 (3 H, s, OCH₃), 3.64 (2 H, t, *J* 7.6 Hz, CH₂-Alk1), 7.31-7.33 (2 H, m, H2,H6-Ar), 7.38-7.46 (3 H, m, H3,H4,H5-Ar). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.6 (C=O), 137.2 (C2-Ind), 132.7 (C1-Ar), 130.4 (C2-Ar), 128.0 (C7a-Ind), 127.7 (C4-Ar), 127.6 (C3-Ar), 118.8 (C3a-Ind), 110.3 (C3-Ind), 49.9 (O<u>CH₃</u>), 44.2 (C5-Alk), 43.1 (C1-Alk), 31.4 (C4-Alk), 29.7 (C2-Alk), 23.5 (C3-Alk), 23.2 (C5-Ind), 23.2 (C4-Ind), 22.8 (C6-Ind), 22.0 (C7-Ind). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 164.9 (N1). HRMS (MALDI) calcd. for $C_{21}H_{26}CINO_2$ [M+Cs]⁺ 492,0701, found 492,0718.


Tetrahydroindoles **5b-k** were obtained in a similar way from appropriate chloropyruvates.¹¹

Methyl 1-(5-chloropentyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5b.



Pale yellow oil; yield 0.89 g, 75% (**5b**); 43 mg, 12% (**6a**); R_f (hexane/EtOAc 2:1) 0.51; [Found: C, 63.9; H, 6.5; N, 3.4. $C_{21}H_{25}Cl_2NO_2$ requires C, 63.96; H, 6.39; Cl, 17.98; N, 3.55]. v_{max} (thin film) 2928, 2853, 1702, 1601, 1523, 1480, 1442, 1410, 1374, 1331, 1269, 1237, 1204, 1154, 1122, 1091, 1015, 965, 824, 785, 755, 734, 650, 612, 507 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.24-1.30 (2 H, m, CH₂-Alk3), 1.44-1.50 (2 H, m, CH₂-Alk2), 1.58-1.64 (2 H, m, CH₂-Alk4), 1.76-1.81 (2 H, m, CH₂-Ind5), 1.84-1.89 (2 H, m, CH₂-Ind6), 2.55 (2 H, br t, *J* 6.0 Hz, CH₂-Ind7), 2.77 (2 H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.42 (2 H, t, *J* 6.6 Hz, CH₂-Alk5), 3.59 (3 H, s, OCH₃), 3.61 (2 H, t, *J* 7.8 Hz, CH₂-Alk1), 7.25 (2H, d, *J* 8.5 Hz, H3,H5-Ar), 7.39 (2H, d, *J* 8.5 Hz, H2,H6-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 136.0 (C2-Ind), 134.1 (C4-Ar), 132.1 (C2-Ar), 131.4 (C1-Ar), 128.7 (C7a-Ind), 128.2 (C3-Ar), 119.3 (C3a-Ind), 111.0 (C3-Ind), 50.3 (OCH₃), 44.4 (C5-Alk), 43.5 (C1-Alk), 31.8 (C4-Alk), 30.1 (C2-Alk), 23.9 (C3-Alk), 23.4 (C5-Ind +C4-Ind), 23.0 (C6-Ind), 22.3 (C7-Ind). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 164.6 (N1).


Methyl 2-(4-bromophenyl)-1-(5-chloropentyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5c.



Yellow oil; yield 0.93 g, 71% (**5c**); 72 mg, 20% (**6a**); R_f (hexane/EtOAc 2:1) 0.73; [Found: C, 57.4; H, 5.9; N, 3.0. $C_{21}H_{25}BrClNO_2$ requires C, 57.48; H, 5.74; Br, 18.21; Cl, 8.08; N, 3.19]. v_{max} (thin film) 2938, 2853, 1697, 1521, 1479, 1442, 1410, 1270, 1204, 1122, 1073, 1011, 822, 785, 755, 735, 650, 502 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.22-1.28 (2H, m, CH₂-Alk3), 1.44-1.50 (2H, m, CH₂-Alk2), 1.58-1.64 (2H, m, CH₂-Alk4), 1.76-1.81 (2H, m, CH₂-Ind5), 1.84-1.89 (2H, m, CH₂-Ind6), 2.55 (2H, br t, *J* 6.0 Hz, CH₂-Ind7), 2.76 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.42 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.59 (3H, s, OCH₃), 3.61 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.18 (2H, d, *J* 8.4 Hz, H3,H5-Ar), 7.54 (2H, d, *J* 8.4 Hz, H2,H6-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 136.0 (C2-Ind), 132.4 (C2-


Ar), 131.9 (C1-Ar), 131.1 (C3-Ar), 128.7 (C7a-Ind), 122.4 (C4-Ar), 119.3 (C3a-Ind), 111.0 (C3-Ind), 50.3 (CO<u>CH₃</u>), 44.4 (C5-Alk), 43.5 (C1-Alk), 31.8 (C4-Alk), 30.1 (C2-Alk), 23.8 (C3-Alk), 23.4 (C4-Ind+C5-Ind), 23.0 (C6-Ind), 22.2 (C7-Ind).

Methyl 1-(5-chloropentyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5d.



Maize yellow oil; yield 0.77 g, 68% (**5d**); 43 mg, 12% (**6a**); R_f (hexane/EtOAc 2:1) 0.59; [Found: C, 66.5; H, 6.4; N, 3.7. C₂₁H₂₅ClFNO₂ requires C, 66.75; H, 6.67; Cl, 9.38; F, 5.03; N, 3.71]. v_{max}(thin film) 2929, 2854, 1702, 1606, 1535, 1489, 1460, 1442, 1412, 1374, 1331, 1269, 1223, 1204, 1156, 1121, 1092, 1016, 965, 833, 821, 787, 735, 651, 591, 523 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ 1.23-1.29 (2H, m, CH₂-Alk3), 1.44-1.50 (2H, m, CH₂-Alk2), 1.57-1.63 (2H, m, CH₂-Alk4), 1.77-1.81 (2H, m, CH₂-Ind5), 1.85-1.89 (2H, m, CH₂-Ind6), 2.55 (2H, br t, *J* 6.2 Hz, CH₂-Ind7), 2.77 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.41 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.59 (3H, s, OCH₃), 3.61 (2H, br t, *J* 7.8 Hz, CH₂-Alk1), 7.11 (2H, dd, *J*_{HH} 8.7 Hz, *J*_{HF} 8.7 Hz, H2,H6-Ar), 7.28 (2H, dd, *J*_{HH} 8.7 Hz, *J*_{HF} 3.0 Hz, H3,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 162.5 (d, ¹*J*_{CF} = 247.5 Hz, C4-Ar), 136.3 (C2-Ind), 132.5 (d, ³*J*_{CF} = 8.2 Hz, C2-Ar), 128.9 (d, ⁴*J*_{CF} = 3.6 Hz, C1-Ar), 128.4 (C7a-Ind), 119.2 (C3a-Ind), 115.0 (d, ²*J*_{CF} = 21.5 Hz, C3-Ar), 110.9 (C3-Ind), 50.3 (O<u>CH₃</u>), 44.4 (C5-Alk), 43.4 (C1-Alk), 31.8 (C4-Alk), 30.1 (C2-Alk), 23.9 (C3-Alk), 23.4 (C4-Ind+C5-Ind), 23.1 (C6-Ind), 22.2 (C7-Ind). ¹⁹F{¹H} NMR (470.5 MHz, CDCl₃): δ 113.7 (F).


Methyl 1-(5-chloropentyl)-2-(4-iodophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5e.



Yellow oil; yield 0.92 g, 63% (**5e**); 79 mg, 22% (**6a**); R_f (hexane/EtOAc 2:1) 0.59; [Found: C, 52.3; H, 5.3; N, 2.7. $C_{21}H_{25}CIINO_2$ requires C, 51.92; H, 5.19; Cl, 7.30; I, 26.12; N, 2.88]. v_{max} (thin film)


2924, 2853, 1702, 1582, 1519, 1475, 1461, 1409, 1376, 1317, 1261, 1238, 1204, 1184, 1154, 1121, 1092, 1023, 1007, 966, 817, 799, 752, 734, 648, 613 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ 1.25-1.31 (2H, m, CH₂-Alk3), 1.46-1.52 (2H, m, CH₂-Alk2), 1.60-1.66 (2H, m, CH₂-Alk4), 1.79-1.82 (2H, m, CH₂-Ind5), 1.86-1.90 (2H, m, CH₂-Ind6), 2.57 (2H, br t, *J* 5.7 Hz, CH₂-Ind7), 2.78 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.44 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.62 (3H, s, OCH₃), 3.63 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.07 (2H, d, *J* 8.3 Hz, H3,H5-Ar), 7.77 (2H, d, *J* 8.3 Hz, H2,H6-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 137.1 (C3-Ar), 136.1 (C2-Ind), 132.6 (C2-Ar), 132.5 (C1-Ar), 128.7 (C7a-Ind), 119.4 (C3a-Ind), 111.0 (C3-Ind), 94.2 (C 4-Ar), 50.4 (O<u>CH₃</u>), 44.5 (C5-Alk), 43.5 (C1-Alk), 31.8 (C4-Alk), 30.1 (C2-Alk), 23.9 (C3-Alk), 23.4 (C5-Ind+C4-Ind), 23.0 (C6-Ind), 22.3 (C-Ind).

Methyl 2-(3-bromophenyl)-1-(5-chloropentyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5f.




Pale yellow oil; yield 1.00 g, 76% (**5f**); 65 mg, 18% (**6a**); R_f (hexane/EtOAc 2:1) 0.53; [Found: C, 57.2; H, 5.8; N, 3.1. $C_{21}H_{25}BrClNO_2$ requires C, 57.48; H, 5.74; Br, 18.21; Cl, 8.08; N, 3.19]. v_{max} (thin film) 2927, 2854, 1703, 1600, 1579, 1561, 1520, 1471, 1441, 1409, 1374, 1330, 1320, 1269, 1238, 1204, 1154, 1122, 1092, 1051, 1030, 997, 964, 890, 784, 755, 714, 700, 652, 535, 437 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.24-1.30 (2H, m, CH₂-Alk3), 1.45-1.51 (2H, m, CH₂-Alk2), 1.58-1.64 (2H, m, CH₂-Alk4), 1.76-1.80 (2H, m, CH₂-Ind5), 1.85-1.89 (2H, m, CH₂-Ind6), 2.55 (2H, br t, *J* 6.1 Hz, CH₂-Ind5), 1.85-1.89 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.59 (3H, s, OCH₃), 3.62 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 7.6 Hz, 1.6, 1.6 Hz, H6-Ar), 7.29 (1H, dd, *J* 7.6, 7.6 Hz, H5-Ar), 7.47 (1H, dd, *J* 1.6, 1.6 Hz, H2-Ar), 7.52 (1H, ddd, *J* 7.6, 1.6, 1.6 Hz, H4-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.7 (C=O), 135.5 (C2-Ind), 135.0 (C1-Ar), 133.6 (C2-Ar), 131.0 (C4-Ar), 129.6 (C5-Ar), 129.3 (C6-Ar), 128.8 (C7a-Ind), 121.7 (C3-Ar), 119.4 (C3a-Ind), 111.1 (C3-Ind), 50.3 (OCH₃), 44.4 (C5-Alk), 43.5 (C1-Alk), 31.7 (C4-Alk), 30.1 (C2-Alk), 23.8 (C3-Alk), 23.4 (C5-Ind), 23.0 (C6-Ind), 22.2 (C7-Ind).

Methyl 1-(5-chloropentyl)-2-(4-nitrophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5g.



Yellow oil; yield 0.92 g, 76% (**5**g); 50 mg, 14% (**6**a); R_f (hexane/EtOAc 2:1) 0.46; [Found: C, 62.0; H, 6.4; N, 6.7. $C_{21}H_{25}ClN_2O_4$ requires C, 62.30; H, 6.22; Cl, 8.76; N, 6.92]. v_{max} (thin film) 2954, 2925, 2854, 1702, 1601, 1579, 1521, 1462, 1414, 1377, 1345, 1261, 1205, 1155, 1122, 1107, 1092, 1047, 1016, 967, 863, 853, 803, 755, 721, 708, 648 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.23-1.29 (2H, m, CH₂-Alk3), 1.43-1.49 (2H, m, CH₂-Alk2), 1.57-1.63 (2H, m, CH₂-Alk4), 1.77-1.82 (2H, m, CH₂-Ind5), 1.86-1.90 (2H, m, CH₂-Ind6), 2.57 (2H, br t, *J* 6.1 Hz, CH₂-Ind7), 2.77 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.41 (2H, t, *J* 6.5 Hz, CH₂-Alk5), 3.60 (3H, s, OCH₃), 3.65 (2H, t, *J* 7.8 Hz, CH₂-Alk1), 7.50 (2H, d, *J* 8.8 Hz, H3,H5-Ar), 8.28 (2H, d, *J* 8.8 Hz, H2,H6-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.5 (C=O), 147.4 (C4-Ar), 139.9 (C1-Ar), 134.5 (C2-Ind), 131.8 (C2-Ar), 129.8 (C7a-Ind), 123.1 (C3-Ar), 119.9 (C3a-Ind), 111.8 (C3-Ind), 50.5 (OCH₃), 44.4 (C5-Alk), 43.7 (C1-Alk), 31.7 (C4-Alk), 30.1 (C2-Alk), 23.8 (C3-Alk), 23.3 (C4-Ind), 23.3 (C5-Ind), 23.0 (C6-Ind), 22.3 (C7-Ind).


Methyl 1-(5-chloropentyl)-2-(3-nitrophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5h.



Yellow oil; yield 0.97 g, 80% (**5h**); 54 mg, 15% (**6a**); R_f (hexane/EtOAc 2:1) 0.48; [Found: C, 62.0; H, 6.4; N, 6.8. $C_{21}H_{25}ClN_2O_4$ requires C, 62.30; H, 6.22; Cl, 8.76; N, 6.92]. v_{max} (thin film) 2926, 2854, 1702, 1619, 1579, 1536, 1519, 1474, 1442, 1407, 1349, 1265, 1238, 1206, 1155, 1126, 1098, 1054, 1025, 965, 908, 858, 807, 787, 739, 711, 697, 651 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.22-1.28 (2H, m, CH₂-Alk3), 1.46-1.52 (2H, m, CH₂-Alk2), 1.57-1.63 (2H, m, CH₂-Alk4), 1.76-1.82 (2H, m, CH₂-Ind5), 1.86-1.90 (2H, m, CH₂-Ind6), 2.57 (2H, br t, *J* 6.0 Hz, CH₂-Ind7), 2.77 (2H, br t, *J* 6.0 Hz, CH₂-Ind4), 3.41 (2H, t, *J* 6.5 Hz, CH₂-Alk5), 3.59 (3H, s, OCH₃), 3.64 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.60 (1H, br dd, *J* 7.6, 7.6 Hz, H5-Ar), 7.68 (1H, br d, *J* 7.6 Hz, H6-Ar), 8.20 (1H, d, *J* 1.3 Hz, H2-Ar), 8.26 (1H, dd, *J* 7.6, 1.3 Hz, H4-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.5 (C=O), 147.9 (C3-Ar), 137.2 (C6-Ar), 134.6 (C1-Ar), 134.3 (C2-Ind), 129.4 (C7a-Ind), 128.8 (C5-Ar), 125.6 (C2-Ar),


122.9 (C4-Ar), 119.7 (C3a-Ind), 111.7 (C3-Ind), 50.5 (OCH₃), 44.4 (C5-Alk), 43.6 (C1-Alk), 31.9 (C4-Alk), 30.2 (C2-Alk), 23.9 (C3-Alk), 23.3 (C4-Ind), 23.3 (C5-Ind), 23.0 (C6-Ind), 22.2 (C7-Ind). HRMS (MALDI) calcd. for $C_{21}H_{25}CIN_2O_4$ [M + Cs]⁺ 537.0552, found 537.0528.

Methyl5-tert-butyl-1-(5-chloropentyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5i.




Maize yellow oil; yield 1.07 g, 82% (**5i**); 40 mg, 11% (**6a**); R_f (hexane/EtOAc 2:1) 0.65; [Found: C, 61.9; H, 6.3; N, 6.6. $C_{25}H_{33}$ ClFNO₂ requires C, 62.30; H, 6.22; Cl, 8.76; N, 6.92]. v_{max} (thin film) 2953, 2868, 1702, 1658, 1604, 1536, 1508, 1488, 1468, 1413, 1396, 1366, 1310, 1224, 1158, 1125, 1095, 1073, 1058, 1015, 918, 838, 788, 753, 733, 651, 620, 591, 524 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ 1.00 (9H, s, (CH₃)₃), 1.22-1.28 (2H, m, CH₂-Alk3), 1.39-1.50 (4H, m, CH₂-Alk2, CH_X-Ind5, CH_A-Ind6), 1.56-1.62 (2H, m, CH₂-Alk4), 2.06-2.11 (1H, m, CH_B-Ind6), 2.37-2.41 (1H, m, CH_A-Ind4), 2.49-2.55 (1H, m, CH₂-Alk5), 3.57 (3H, s, OCH₃), 3.60 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.09 (2H, dd, *J*_{HH} 8.8 Hz, *H*₂, H2, H6-Ar), 7.27 (2H, dd, *J*_{HH} 8.8 Hz, *J*_{HF} 3.4 Hz, H3,H5-Ar). ¹³C{¹H} NMR (100.6 MHz, CDCl₃): δ 165.8 (C=O), 162.5 (d, ¹*J*_{CF} = 247.6 Hz, C4-Ar), 136.4 (C2-Ind), 132.4 (d, ³*J*_{CF} = 8.2 Hz, C2-Ar), 128.9 (d, ⁴*J*_{CF} = 3.3 Hz, C1-Ar), 128.6 (C7a-Ind), 119.6 (C3a-Ind), 114.9 (d, ²*J*_{CF} = 21.6 Hz, C3-Ar), 110.9 (C3-Ind), 50.2 (OCH₃), 45.3 (C5-Ind), 44.4 (C5-Alk), 43.5 (C1-Alk), 32.5 (<u>C</u>-(CH₃)₃), 31.7 (C4-Alk), 30.0 (C2-Alk), 27.4 (C-(<u>C</u>H₃)₃), 24.6 (C4-Ind), 24.5 (C6-Ind), 23.8 (C3-Alk), 23.1 (C7-Ind). ¹⁹F{¹H} NMR (376.5 MHz, CDCl₃): δ 113.5 (F).

Ethyl 1-(5-bromopentyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5j.




Yellow oil; yield 1.02 g, 78% (**5j**); 60 mg, 12% (**6a**); R_f (hexane/EtOAc 2:1) 0.60; [Found: C, 60.1; H, 6.4; N, 3.0. $C_{22}H_{27}BrFNO_2$ requires C, 60.55; H, 6.24; Br, 18.31; F, 4.35; N, 3.21]. v_{max} (thin film) 2936, 2857, 1732, 1697, 1600, 1509, 1489, 1459, 1414, 1255, 1158, 1117, 1094, 1038, 838, 523 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.06 (3H, t, *J* 7.1, OCH₂CH₃), 1.22-1.28 (2H, m, CH₂-Alk3), 1.44-1.50 (2H, m, CH₂-Alk2), 1.65-1.71 (2H, m, CH₂-Alk4), 1.77-1.81 (2H, m, CH₂-Ind5), 1.85-1.89 (2H, m, CH₂-Ind6), 2.55 (2H, br t, *J* 5.9 Hz, CH₂-Ind7), 2.78 (2H, br t, *J* 5.9 Hz, CH₂-Ind4), 3.28 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.60 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 4.04 (2H, q, *J* 7.1 Hz, OCH₂CH₃), 7.10 (2H, dd, *J_{HH}* 8.6 Hz, *J_{HF}* 8.6 Hz, H2,H6-Ar), 7.28 (2H, dd, *J_{HH}* 8.6 Hz, *J_{HF}* 3.0 Hz, H3,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.3 (C=O), 162.5 (d, ¹*J*_{CF} = 247.1 Hz, C4-Ar), 136.1 (C2-Ind), 132.5 (d, ³*J*_{CF} = 8.2 Hz, C2-Ar), 129.0 (d, ²*J*_{CF} = 3.4 Hz, C1-Ar), 128.4 (C7a-Ind), 119.2 (C3a-Ind), 114.9 (d, ²*J*_{CF} = 21.6 Hz, C3-Ar), 111.2 (C3-Ind), 58.8 (OCH₂CH₃), 43.4 (C1-Alk), 33.1 (C5-Alk), 31.8 (C4-Alk), 29.9 (C2-Alk), 25.1 (C3-Alk), 23.4 (C5-Ind), 23.3 (C4-Ind), 23.0 (C6-Ind), 22.2 (C7-Ind), 14.1 (OCH₂CH₃). ¹⁹F{¹H} NMR (470.5 MHz, CDCl₃): δ -113.8 (F).

Methyl 1-(5-chloropentyl)-2-hexyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5k.




Colorless oil; yield 0.75 g, 68% (**5**j); 50 mg, 14% (**6**a); R_f (hexane/EtOAc 2:1) 0.60; [Found: C, 68.4; H, 9.6; N, 3.6. $C_{21}H_{24}CINO_2$ requires C, 68.55; H, 9.31; Cl, 9.64; N, 3.81]. v_{max} (thin film) 2931, 2856, 1695, 1518, 1441, 1422, 1328, 1259, 1237, 1187, 1155, 1113, 1032, 786, 732, 653 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 0.89 (3H, t, *J* 6.8 Hz, CH₂-Alk2-6), 1.26-1.34 (4H, m, CH₂-Alk2-4, CH₂-Alk2-5), 1.37-1.43 (2H, m, CH₂-Alk2-3), 1.47-1.56 (4H, m, CH₂-Alk2-2, CH₂-Alk1-3), 1.61-1.67 (2H, m, CH₂-Alk1-2), 1.71-1.74 (2H, m, CH₂-Ind5), 1.77-1.83 (4H, m, CH₂-Ind6, CH₂-Alk1-4), 2.47 (2H, br t, *J* 5.8 Hz, CH₂-Ind7), 2.68 (2H, br t, *J* 5.9 Hz, CH₂-Ind4), 2.87 (2H, br t, *J* 8.0 Hz, CH₂-Alk2-1), 3.54 (2H, t, *J* 6.5 Hz, CH₂-Alk1-5), 3.71 (2H, t, *J* 7.8 Hz, CH₂-Alk1-1), 3.76 (3H, s, OCH₃). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 166.4 (C=O), 139.4 (C2-Ind), 126.9 (C7a-Ind), 118.5 (C3a-Ind), 108.6 (C3-Ind), 50.1 (OCH₃), 44.5 (C5-Alk1), 42.9 (C1-Alk1), 32.1 (C4-Alk1), 31.6 (C4-Alk2), 30.6 (C2-Alk1), 30.5 (C2-Alk2), 29.5 (C3-Alk2), 25.5 (C1-Alk2), 24.2 (C3-Alk1), 23.5 (C4-Ind+C5-Ind), 23.1 (C6-Ind), 22.6 (C5-Alk2), 22.1 (C7-Ind), 14.0 (C6-Alk2). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 163.7 (N). HRMS (MALDI) calcd. for $C_{21}H_34$ CINO₂ [M+Cs]⁺ 500.1327, found 500.1354.

Methyl 5-tert-butyl-1-(5-chloropentyl)-2-phenyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5l.



Maize yellow oil; yield 0.99 g, 79% (**5**l); 54 mg, 15% (**6a**); R_f (hexane/EtOAc 2:1) 0.60; [Found: C, 71.9; H, 8.5; N, 3.2. $C_{25}H_{34}ClNO_2$ requires C, 72.18; H, 8.24; Cl, 8.52; N, 3.37]. v_{max} (thin film) 2953, 2926, 2855, 1703, 1480, 1444, 1407, 1366, 1310, 1207, 1165, 1124, 1098, 761, 702 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.00 (9H, s, (CH₃)₃), 1.22-1.30 (2H, m, CH₂-Alk3), 1.42-1.51 (4H, m, CH₂-Alk2, CH_X-Ind5, CH_A-Ind6), 1.55-1.60 (2H, m, CH₂-Alk4), 2.09-2.12 (1H, m, CH_B-Ind6), 2.40-2.43 (1H, m, CH_A-Ind4), 2.51-2.54 (1H, m, CH_A-Ind7), 2.65-2.68 (1H, m, CH_B-Ind7), 3.00-3.03 (1H, m, CH_B-Ind4), 3.39 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.57 (3H, s, OCH₃), 3.63 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 7.31 (2H, dd, *J* 8.0, 1.7 Hz, H2,H6-Ar), 7.38-7.43 (3H, m, H3,H4,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.9 (C=O), 137.7 (C2-Ind), 133.0 (C1-Ar), 130.7 (C2-Ar), 128.4 (C7a-Ind), 127.9 (C4-Ar), 127.8 (C3-Ar), 119.6 (C3a-Ind), 110.6 (C3-Ind), 50.2 (OCH₃), 45.4 (C5-Ind), 44.4 (C5-Alk), 43.5 (C1-Alk), 32.5 (<u>C</u>(CH₃)₃), 31.7 (C4-Alk), 30.0 (C2-Alk), 27.5 (C(<u>CH₃)₃</u>), 24.7 (C4-Ind), 24.5 (C6-Ind), 23.8 (C3-Alk), 23.1 (C7-Ind). HRMS (MALDI) calcd. for C₂₅H₃₄ClNO₂ [M+Cs]⁺ 548.1327, found 548.1320.

Ethyl 1-(5-bromopentyl)-2-phenyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 5m.



Yellow oil; yield 0.83 g, 66% (**5**l); 0.11 g, 22% (**6a**); R_f (hexane/EtOAc 2:1) 0.50; [Found: C, 63.0; H, 7.0; N, 3.2. $C_{25}H_{34}CINO_2$ requires C, 63.16; H, 6.75; Br, 19.10; N, 3.35]. v_{max} (thin film) 2935, 1752, 1695, 1484, 1454, 1264, 1202, 1158, 1115, 754, 700 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.00 (3H, t, *J* 7.1 Hz, OCH₂CH₃), 1.23-1.27 (2H, m, CH₂-Alk3), 1.44-1.50 (2H, m, CH₂-Alk2), 1.62-1.68 (2H, m, CH₂-Alk4), 1.78-1.82 (2H, m, CH₂-Ind5), 1.85-1.90 (2H, m, CH₂-Ind6), 2.56 (2H, br t, *J* 6.1 Hz,

CH₂-Ind7), 2.80 (2H, br t, *J* 6.0 Hz, CH₂-Ind4), 3.25 (2H, t, *J* 6.7 Hz, CH₂-Alk5), 3.62 (2H, t, *J* 7.7 Hz, CH₂-Alk1), 4.03 (2H, q, *J* 7.1 Hz, O<u>CH₂</u>CH₃), 7.30 (2H, dd, *J* 7.9, 2.1 Hz, H2,H6-Ar), 7.37-7.40 (3H, m, H3,H4,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.4 (C=O), 137.4 (C2-Ind), 133.1 (C1-Ar), 130.8 (C2-Ar), 128.2 (C7a-Ind), 127.9 (C4-Ar), 127.8 (C3-Ar), 119.2 (C3a-Ind), 110.9 (C3-Ind), 58.8 (O<u>C</u>H₂CH₃), 43.4 (C1-Alk), 33.1 (C5-Alk), 31.9 (C4-Alk), 29.9 (C2-Alk), 25.1 (C3-Alk), 23.5 (C4-Ind), 23.3 (C5-Ind), 23.1 (C6-Ind), 22.3 (C7-Ind), 14.0 (OCH₂CH₃). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 164.4 (N).

Piperidinium chloride 6a.




Off-white powder, m.p. 247-248 °C; [Found: C, 49.3; H, 10.0; N, 11.3. C₅H₁₂ClN: C, 49.38; H, 9.95; Cl, 29.15; N, 11.52]. v_{max} (thin film) 2950, 2842, 2809, 2763, 2735, 2527, 2428, 1593, 1462, 1437, 1032, 943, 557 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta_{\rm H}$ 1.51-1.57 (2H, m, CH₂-4), 1.65-1.70 (4H, m, CH₂-3,CH₂-5), 2.95 (4H, t, *J* 5.7 Hz, CH₂-2,CH₂-6), 9.15 (2H, br s, NH₂). ¹³C{¹H} NMR (100.6 MHz, DMSO-*d*₆): δ 43.3 (C2, C6), 21.9 (C3, C5), 21.7 (C4). ¹⁵N NMR (50.6 MHz, DMSO-*d*₆): δ 41.5 (N).

Piperidinium bromide 6b.




Off-white powder, m.p. 334-336 °C; [Found: C, 36.0; H, 7.5; N, 8.3. C₅H₁₂BrN: C, 36.16; H, 7.28; Br, 48.12; N, 8.43]. v_{max} (thin film) 3177, 2949, 2840, 2808, 2738, 2627, 2513, 2413, 1586, 1462, 1434, 1030, 551 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta_{H} \delta$ 1.51-1.57 (2H, m, CH₂-4), 1.63-1.68 (4H, m, CH₂-3,CH₂-5), 3.00 (4H, t, *J* 5.0 Hz, CH₂-2,CH₂-6), 8.42 (2H, br s, NH₂). ¹³C{¹H} NMR (100.6 MHz, DMSO-*d*₆): δ 43.8 (C2, C6), 22.1 (C3, C5), 21.6 (C4).

2-Phenyl-1-(piperidin-1-yl)ethanone 7a.



Colorless oil; yield 24 mg, 4%; R_f (hexane/EtOAc 2:1) 0.60; [Found: C, 76.5; H, 8.6; N, 6.7. $C_{13}H_{17}NO$ requires C, 76.81; H, 8.43; N, 6.89]. v_{max} (thin film) 3028, 3005, 2937, 2856, 1738, 1640, 1444, 1368, 1256, 1225, 1136, 1123, 1022, 726, 698 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): δ_H 1.29-1.33 (2H, m, CH₂-3), 1.37-1.41 (2H, m, CH₂-5), 1.51-1.55 (2H, m, CH₂-4), 3.40 (2H, t, *J* 5.6 Hz, CH₂-2), 3.43 (2H, t, *J* 5.6 Hz, CH₂-6), 3.68 (2H, s, CH₂), 7.21 (1H, t, *J* 7.4 Hz, H4'), 7.22 (2H, d, *J* 7.7 Hz, H2', H6'), 7.30 (2H, dd, *J* 7.4, 7.7 Hz, H3', H5'). ¹³C{¹H} NMR (125.7 MHz, DMSO-*d*₆): δ 168.3 (C=O), 136.0 (C1-Ar), 128.7 (C2-Ar), 128.2 (C3-Ar), 126.2 (C4-Ar), 46.4 (C2), 42.0 (C6), 39.7 (CH₂), 25.8 (C3), 25.2 (C5), 23.9 (C4). ¹⁵N NMR (50.6 MHz, DMSO-*d*₆): δ 121.1 (N1). HRMS (MALDI) calcd. for C₁₃H₁₇NO [M+Cs]⁺ 336.0359, found 336.0330.

2-(4-nitrophenyl)-1-(piperidin-1-yl)ethanone 7b.




Yellow oil; yield 45 mg, 6%; R_f (hexane/EtOAc 2:1) 0.60; Found: C, 62.8; H, 6.7; N, 11.1. $C_{13}H_{16}N_2O_3$ requires C, 62.89; H, 6.50; N, 11.28. v_{max} (thin film) 2932, 1923, 2854, 1736, 1632, 1606, 1517, 1443, 1423, 1346, 1250, 1225, 1135, 1109, 1013, 857, 820, 734 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): δ_H 1.44-1.46 (2H, m, CH₂-3), 1.53-1.55 (2H, m, CH₂-5), 1.60-1.63 (2H, m, CH₂-4), 3.40 (2H, t, *J* 5.3 Hz, CH₂-2), 3.58 (2H, t, *J* 5.3 Hz, CH₂-6), 3.81 (2H, s, CH₂), 7.42 (2H, d, *J* 8.8 Hz, H2', H6'), 8.17 (2H, d, *J* 8.8 Hz, H3', H5'). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 167.7 (C=O), 147.0 (C4-Ar), 143.0 (C1-Ar), 129.8 (C2-Ar), 123.7 (C3-Ar), 47.2 (C2), 43.1 (C6), 40.4 (CH₂), 26.4 (C3), 25.4 (C5), 24.3 (C4). ¹⁵N NMR (50.6 MHz, CDCl₃) δ 124.5 (N1), 370.0 (NO₂). HRMS (MALDI) calcd. for $C_{13}H_{16}N_2O_3$ [M+Cs]⁺ 381.0210, found 381.0240.

4.4. General procedure for the synthesis of 3.


A solution of pyrrolidine (5 mmol) and cyclohexanone a (5 mmol) in benzene (25 mL) was heated to reflux with the Dean-Stark apparatus for 1 h, then cooled to room temperature and methyl 3-chloro-2-oxo-3-arylpropanoate 2 (5 mL) in benzene was added then heated to reflux for another 2 h. The solvent was removed to give a slightly yellow crude product 3, which was purified on column chromatography with silica gel (eluent – hexane/EtOAc).

Methyl 1-(4-chlorobutyl)-2-phenyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 3a.



Colorless oil; yield 1.69 g, 98%; R_f (hexane/EtOAc 2:1) 0.53; [Found: C, 69.1; H, 6.8; N, 3.9. $C_{20}H_{24}CINO_2$ requires C, 69.45; H, 6.99; Cl, 10.25; N, 4.05]. v_{max} (thin film) 2933, 2853, 1702, 1527, 1481, 1459, 1441, 1406, 1370, 1276, 1250, 1204, 1154, 1120, 1086, 1025, 757, 702 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.52-1.58 (2H, m, CH₂-Alk3), 1.58-1.64 (2H, m, CH₂-Alk2), 1.78-1.82 (2H, m, CH₂-Ind5), 1.86-1.90 (2H, m, CH₂-Ind6), 2.58 (2H, br t, *J* 6.0 Hz, CH₂-Ind7), 2.79 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.32 (2H, t, *J* 6.3 Hz, CH₂-Alk4), 3.58 (3H, s, OCH₃), 3.66 (2H, t, *J* 7.4 Hz, CH₂-Alk1), 7.30-7.32 (2H, m, H2,H6-Ar), 7.38-7.43 (3H, m, H3,H4,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 137.5 (C2-Ind), 132.8 (C1-Ind), 130.7 (C2-Ar), 128.2 (C7a-Ind), 128.0 (C4-Ar), 127.9 (C3-Ar), 119.2 (C3a-Ind), 110.7 (C3-Ind), 50.2 (OCH₃), 44.0 (C4-Alk), 42.8 (C1-Alk), 29.3 (C3-Alk), 27.9 (C2-Alk), 23.4 (C5-Ind), 23.3 (C4-Ind), 23.0 (C6-Ind), 22.2 (C7-Ind). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 163.9 (N).


Methyl 1-(4-chlorobutyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 3b.



Maize yellow oil; yield 1.56 g, 82%; R_f (hexane/EtOAc 2:1) 0.51; [Found: C, 63.0; H, 6.3; N, 3.5. $C_{20}H_{23}Cl_2NO_2$ requires C, 63.16; H, 6.10; Cl, 18.64; N, 3.68]. v_{max} (thin film) 2922, 2850, 1701, 1525,


1479, 1449, 1440, 1400, 1368, 1276, 1265, 1233, 1200, 1152, 1124, 1085, 1010, 965, 824, 786, 750, 734 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta_{\rm H}$ 1.54-1.64 (4H, m, CH₂-Alk2, CH₂-Alk3), 1.76-1.82 (2H, m, CH₂-Ind5), 1.84-1.90 (2H, m, CH₂-Ind6), 2.56 (2H, br t, *J* 6.1 Hz, CH₂-Ind7), 2.77 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.36 (2H, t, *J* 6.2 Hz, CH₂-Alk4), 3.60 (3H, s, OCH₃), 3.65 (2H, t, *J* 7.3 Hz, CH₂-Alk1), 7.25 (2H, d, *J* 8.5 Hz, H3,H5-Ar), 7.40 (2H, d, *J* 8.5 Hz, H2,H6-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.7 (C=O), 136.1 (C2-Ind), 134.2 (C4-Ar), 132.1 (C2-Ar), 131.3 (C1-Ar), 128.7 (C7a-Ind), 128.2 (C3-Ar), 119.4 (C3a-Ind), 111.1 (C3-Ind), 50.3 (OCH₃), 44.0 (C4-Alk), 42.9 (C1-Alk), 29.4 (C3-Alk), 28.0 (C2-Alk), 23.4 (C5-Ind+C4-Ind), 23.0 (C6-Ind), 22.3 (C7-Ind). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 163.8 (N1).

Methyl 1-(4-chlorobutyl)-2-(4-bromophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 3c.



Yellow oil; yield 1.87 g, 88%; R_f (hexane/EtOAc 2:1) 0.73; [Found: C, 56.3; H, 5.6; N, 3.2. $C_{20}H_{23}BrClNO_2$ requires C, 56.55; H, 5.46; Br, 18.81; Cl, 8.35; N, 3.30]. v_{max} (thin film) 2935, 2853, 1699, 1520, 1480, 1440, 1406, 1266, 1274, 1210, 1204, 1128, 1120, 1075, 1021, 757, 735 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): δ_H 1.54-1.58 (2H, m, CH₂-Alk3), 1.59-1.63 (2H, m, CH₂-Alk2), 1.78-1.80 (2H, m, CH₂-Ind5), 1.86-1.88 (2H, m, CH₂-Ind6), 2.56 (2H, br t, *J* 6.1 Hz, CH₂-Ind7), 2.76 (2H, br t, *J* 6.1 Hz, CH₂-Ind4), 3.36 (2H, t, *J* 6.2 Hz, CH₂-Alk4), 3.59 (3H, s, OCH₃), 3.64 (2H, t, *J* 7.3 Hz, CH₂-Alk1), 7.18 (2H, d, *J* 8.4 Hz, H3,H5-Ar), 7.55 (2H, d, *J* 8.4 Hz, H2,H6-Ar). ¹³C{¹H} NMR (150.9 MHz, CDCl₃): δ 165.7 (C=O), 136.0 (C2-Ind), 132.4 (C1-Ar), 132.4 (C2-Ar), 131.2 (C3-Ar), 128.7 (C7a-Ind), 122.4 (C4-Ar), 119.5 (C3a-Ind), 111.2 (C3-Ind), 50.3 (OCH₃), 44.0 (C4-Alk), 42.9 (C1-Alk), 29.4 (C3-Alk), 28.1 (C2-Alk), 23.4 (C4-Ind+C5-Ind), 23.1 (C6-Ind), 22.3 (C7-Ind).

Methyl 1-(4-chlorobutyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 3d.




Colorless oil; yield 1.67 g, 92%; R_f (hexane/EtOAc 2:1) 0.59; [Found: C, 65.9; H, 6.6; N, 3.7. $C_{20}H_{23}ClFNO_2$ requires C, 66.02; H, 6.37; Cl, 9.74; F, 5.22; N, 3.85]. v_{max} (thin film) 2924, 2850, 1704, 1600, 1527, 1480, 1459, 1441, 1406, 1370, 1276, 1250, 1204, 1154, 1122, 1090, 1025, 757, 732, 702, 646, 592, 521 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.55-1.61 (4H, m, CH₂-Alk2, CH₂-Alk3), 1.78-1.81 (2H, m, CH₂-Ind5), 1.85-1.88 (2H, m, CH₂-Alk6), 2.56 (2H, br t, *J* 6.0 Hz, CH₂-Ind7), 2.77 (2H, br t, *J* 6.0 Hz, CH₂-Ind4), 3.35 (2H, t, *J* 6.1 Hz, CH₂-Alk4), 3.59 (3H, s, OCH₃), 3.64 (2H, t, *J* 7.4 Hz, CH₂-Alk1), 7.11 (2H, dd, *J_{HH}* 8.7 Hz, *J_{HF}* 8.7 Hz, H2,H6-Ar), 7.28 (2H, dd, *J_{HH}* 8.7 Hz, *J_{HF}* 3.0 Hz, H3,H5-Ar). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 165.8 (C=O), 162.6 (d, ¹*J*_{CF} 247.9 Hz, C4-Ar), 136.4 (C2-Ind), 132.5 (d, ³*J*_{CF} 8.2 Hz, C2-Ar), 128.8 (d, ⁴*J*_{CF} 3.1 Hz, C1-Ar), 128.5 (C7a-Ind), 119.3 (C3a-Ind), 115.0 (d, ²*J*_{CF} 21.4 Hz, C3-Ar), 111.1 (C3-Ind), 50.3 (OCH₃), 44.0 (C4-Alk), 42.9 (C1-Alk), 29.7 (C3-Alk), 28.0 (C2-Alk), 23.4 (C4-Ind+C5-Ind), 23.1 (C6-Ind), 22.3 (C7-Ind). ¹⁹F{¹H} NMR (470.5 MHz, CDCl₃): δ 113.6 (F). HRMS (MALDI) calcd. for $C_{20}H_{23}ClFNO_2$ [M + Cs]⁺ 496.0450, found 496.0414.

General procedure for the synthesis of 10.

4.5. A solution of **3** or **5** (0.5 mmol) and 0.61 g of chloranil (2.5 mmol) in *p*-xylene (20 mL) was heated at reflux for 17 h, cooled, filtered and the solid residue was washed with ether (3×5 mL). The solvent was evaporated in vacuo and the residue was chromatographed (hexane : EtOAc) to give a pure indole derivative **10**.


Methyl 1-(5-chloropentyl)-2-phenyl-1H-indole-3-carboxylate 10a.



Colorless oil; yield 1.45 g, 85%; R_f (hexane/EtOAc 2:1) 0.40; [Found: C, 70.1; H, 6.0; N, 3.9. $C_{20}H_{20}CINO_2$ requires C, 70.27; H, 5.90; Cl, 10.37; F, 5.22; N, 4.10]. v_{max} (thin film) 2951, 2927, 1694, 1541, 1483, 1460, 1406, 1234, 1190, 1146, 1117, 1092. 1026, 791, 753, 701, 646 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.48-1.54 (2H, m, CH₂-Alk3), 1.63-1.69 (2H, m, CH₂-Alk2), 3.44 (2H, t, *J* 6.5, CH₂-Alk4), 3.60 (3H, s, OCH₃), 4.05 (2H, t, *J* 7.3 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 7.5, 7.4, 1.1 Hz, H5-Ind), 7.31 (1H, ddd, *J* 7.0, 6.8, 1.3 Hz, H6-Ind), 7.43-7.46 (2H, m, H3,H5-Ar), 7.51-7.53 (3H, m,


H2,H4, H6-Ar), 7.75 (1H, br d, *J* 8.2 Hz, H7-Ind), 8.09 (1H, br d, *J* 6.3 Hz, H4-Ind). ¹³C{¹H} NMR (125.7 MHz, CDCl₃): δ 164.3 (C=O), 146.1 (C2-Ind), 135.6 (C7a-Ind), 131.0 (C1-Ar), 130.1 (C2-Ar), 128.8 (C4-Ar), 128.0 (C3-Ar), 126.0 (C3a-Ind), 122.7 (C6-Ind), 121.8 (C5-Ind), 121.2 (C4-Ind), 110.9 (C7-Ind), 104.2 (C3-Ind), 50.3 (OCH₃), 44.5 (C4-Alk), 42.6 (C1-Alk), 29.0 (C3-Alk), 26.5 (C2-Alk). ¹⁵N NMR (50.6 MHz, CDCl₃): δ 150.8 (N1). HRMS (MALDI) calcd. for C₂₀H₂₀ClNO₂ [M+Cs]⁺ 474.0232, found 474.0249.

Methyl 2-(4-bromophenyl)-1-(4-chlorobutyl)-1H-indole-3-carboxylate 10c.



Sallow oil; yield 1.72 g, 82%; R_f (hexane/EtOAc 2:1) 0.63; [Found: C, 56.9; H, 5.0; N, 3.2. $C_{20}H_{19}BrCINO_2$ requires C, 57.09; H, 4.55; Br, 18.99; Cl, 8.43; N, 3.33]. v_{max} (thin film) 3598, 3160, 2142, 1660, 1040, 1014, 968, 889, 756, 656 cm^{-1. 4}H NMR (500 MHz, CDCl₃): δ_H 1.50-1.56 (2H, m, CH₂-Alk3), 1.62-1.68 (2H, m, CH₂-Alk2), 3.47 (2H, t, *J* 6.5 Hz, CH₂-Alk4), 3.63 (3H, s, OCH₃), 4.06 (2H, t, *J* 7.3 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 8.1, 7.2, 1.1 Hz, H5-Ind), 7.32 (1H, ddd, *J* 8.0, 7.2, 1.3 Hz, H6-Ind), 7.41 (2H, d, *J* 8.5 Hz, H3,H5-Ar), 7.66 (1H, br d, *J* 8.0 Hz, H7-Ind), 7.72 (2H, d, *J* 8.5 Hz, H2,H6-Ar), 8.09 (1H, dd, *J* 8.0, 1.0 Hz, H4-Ind). ¹³C{¹H} NMR (100.6 MHz, DMSO-*d*₆): δ 164.2 (C=O), 144.7 (C2-Ind), 135.7 (C7a-Ind), 132.3 (C2-Ar), 131.0 (C3-Ar), 130.3 (C1-Ar), 125.9 (C3a-Ind), 122.8 C6-Ind), 122.5 (C4-Ar), 121.9 (C5-Ind), 121.2 (C4-Ind), 111.0 (C7-Ind), 104.5 (C3-Ind), 50.4 (OCH₃), 44.5 (C4-Alk), 42.7 (C1-Alk), 29.0 (C3-Alk), 26.5 (C2-Alk).


Methyl 2-(4-fluorophenyl)-1-(4-chlorobutyl)-1H-indole-3-carboxylate 10d.



Reddish-brown oil; yield 1.55 g, 86%; R_f (hexane/EtOAc 2:1) 0.51; [Found: C, 66.7; H, 5.5; N, 3.7. $C_{20}H_{19}CIFNO_2$ requires C, 66.76; H, 5.32; Cl, 9.85; F, 5.28; N, 3.89]. v_{max} (thin film) 3580, 3176,


2262, 1650, 1038, 1022, 988, 860, 781, 744, 720, 662, 635 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta_{\rm H}$ 1.49-1.56 (2H, m, CH₂-Alk3), 1.62-1.69 (2H, m, CH₂-Alk2), 3.46 (2H, t, *J* 6.4 Hz, CH₂-Alk4), 3.62 (3H, s, OCH₃), 4.05 (2H, t, *J* 7.3 Hz, CH₂-Alk1), 7.24-7.31 (2H, m, H5,H6-Ind), 7.35 (2H, dd, *J_{HH}* 8.7 Hz, *J_{HF}* 8.7 Hz, H2,H6-Ar), 7.51 (2H, dd, *J_{HH}* 8.7 Hz, *J_{HF}* 3.0 Hz, H3,H5-Ar), 7.66 (1H, d, *J* 8.0 Hz, H7-Ind), 8.09 (1H, d, *J* 8.1 Hz, H4-Ind). ¹³C{¹H} NMR (100.6 MHz, DMSO-*d*₆): δ 164.3 (C=O), 162.4 (d, ¹*J*_{CF} = 245.7 Hz, C4-Ar), 145.0 (C2-Ind), 135.7 (C7a-Ind), 132.5 (d, ³*J*_{CF} 8.4 Hz, C2-Ar), 127.4 (d, ⁴*J*_{CF} 3.2 Hz, C1-Ar), 125.9 (C3a-Ind), 122.8 (C6-Ind), 121.8 (C5-Ind), 121.2 (C4-Ind), 115.0 (d, ²*J*_{CF} 21.7 Hz, C3-Ar), 111.0 (C7-Ind), 104.5 (C3-Ind), 50.4 (OCH₃), 44.5 (C4-Alk), 42.6 (C1-Alk), 29.0 (C3-Alk), 26.5 (C2-Alk). ¹⁹F{¹H} NMR (376.5 MHz, DMSO-*d*₆): δ 112.6 (F). HRMS (MALDI) calcd. for C₂₀H₁₉FCINO₂ [M+H]⁺ 360.1161, found 360.1132.

Methyl 2-(4-nitrophenyl)-1-(4-chlorobutyl)-1H-indole-3-carboxylate 10g.




Brown oil; yield 1.78 g, 92%; R_f (hexane/EtOAc 2:1) 0.50; [Found: C, 61.9; H, 5.2; N, 7.1. $C_{20}H_{19}ClN_2O_4$ requires C, 62.10; H, 4.95; Cl, 9.17; N, 7.24]. v_{max} (thin film) 2498, 2864, 1688, 1603, 1520, 1485, 1457, 1439, 1389, 1348, 1194, 1160, 1145, 1119, 1017, 860, 790, 754, 710 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): δ_H 1.50-1.55 (2H, m, CH₂-Alk3), 1.62-1.67 (2H, m, CH₂-Alk2), 3.47 (2H, t, *J* 6.6 Hz, CH₂-Alk4), 3.63 (3H, s, OCH₃), 4.09 (2H, t, *J* 7.5 Hz, CH₂-Alk1), 7.30 (1H, dd, *J* 7.0, 7.9 Hz, H5-Ind), 7.35 (1H, ddd, *J* 7.0, 7.9, 0.9 Hz, H6-Ind), 7.71 (1H, br d, *J* 7.9 Hz, H7-Ind), 7.79 (2H, d, *J* 8.8 Hz, H2,6-Ind), 8.11 (1H, br d, *J* 7.9 Hz, H4-Ind), 8.36 (2H, d, *J* 8.8 Hz, H3,5-Ar). ¹³C{¹H} NMR (150.9 MHz, DMSO-*d*₆): δ 164.1 (C=O), 147.7 (C4-Ar), 143.5 (C2-Ind), 138.0 (C1-Ar), 136.0 (C7a-Ind), 131.9 (C2-Ar), 125.7 (C3a-Ind), 123.1 (C6-Ind), 123.0 (C3-Ar), 122.1 (C5-Ind), 121.3 (C4-Ind), 111.1 (C7-Ind), 105.0 (C3-Ind), 50.5 (OCH₃), 44.5 (C4-Alk), 42.8 (C1-Alk), 28.9 (C3-Alk), 26.5 (C2-Alk). ¹⁵N NMR (50.6 MHz, DMSO-*d*₆): δ 150.2 (N1), 370.4 (NO₂).

Methyl 1-(5-chloropentyl)-2-(4-chlorophenyl)-1H-indole-3-carboxylate 11b.



Maize yellow oil; yield 1.39 g, 71%; R_f (hexane/EtOAc 2:1) 0.56; [Found: C, 64.5; H, 5.5; N, 3.4. $C_{21}H_{21}Cl_2NO_2$ requires C, 64.62; H, 5.42; Cl, 18.17; N, 3.59]. v_{max} (thin film) 3622, 3154, 2257, 2130, 1665, 1153, 1053, 1041, 1016, 979, 828, 772, 669 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ_H 1.14-1.22 (2H, m, CH₂-Alk3), 1.48-1.59 (4H, m, CH₂-Alk2, CH₂-Alk4), 4.02 (2H, t, *J* 7.5 Hz, CH₂-Alk5), 3.62 (3H, s, OCH₃), 4.02 (2H, t, *J* 7.5 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 7.2, 7.7, 1.2 Hz, H5-Ind), 7.31 (1H, ddd, *J* 7.2, 7.9, 1.3 Hz, H6-Ind), 7.48 (2H, d, *J* 8.6 Hz, H3,H5-Ar), 7.58 (2H, d, *J* 8.6 Hz, H2,H6-Ind), 7.64 (1H, br d, *J* 7.9 Hz, H7-Ind), 8.09 (1H, dd, *J* 7.7, 1.3 Hz, H4-Ind). ¹³C{¹H} NMR (150.9 MHz, DMSO-*d*₆): δ 164.3 (C=O), 144.7 (C2-Ind), 135.7 (C7a-Ind), 133.8 (C4-Ar), 132.1 (C2-Ar), 130.0 (C1-Ar), 128.1 (C3-Ar), 125.9 (C3a-Ind), 122.8 (C6-Ind), 121.8 (C5-Ind), 121.2 (C4-Ind), 111.0 (C7-Ind), 104.4 (C3-Ind), 50.4 (OCH₃), 44.9 (C5-Alk), 43.2 (C1-Alk), 31.2 (C4-Alk), 28.3 (C2-Alk), 23.3 (C3-Alk). HRMS (MALDI) calcd. for $C_{21}H_{21}Cl_2NO_2$ [M+Cs]⁺ 521.9998, found 522.0021.


Methyl 1-(5-chloropentyl)-2-(4-bromophenyl)-1H-indole-3-carboxylate 11c.



Yellow oil; yield 1.50 g, 69%; R_f (hexane/EtOAc 2:1) 0.58; [Found: C, 57.7; H, 5.0; N, 3.1. $C_{21}H_{21}BrCINO_2$ requires C, 58.02; H, 4.87; Br, 18.38; Cl, 8.15; N, 3.22]. v_{max} (thin film) 3603, 3175, 2257, 2130, 1666, 1649, 1041, 1014, 979, 827, 754 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.14-1.21 (2H, m, CH₂-Alk3), 1.48-1.59 (4H, m, CH₂-Alk2, CH₂-Alk4), 3.48 (2H, t, *J* 6.7 Hz, CH₂-Alk5), 3.63 (3H, s, OCH₃), 4.02 (2H, t, *J* 7.5 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 7.6, 7.8, 1.1 Hz, H5-Ind), 7.31 (1H, ddd, *J* 7.6, 8.1, 1.3 Hz, H6-Ind), 7.42 (2H, d, *J* 8.5 Hz, H3,H5-Ar), 7.65 (1H, br d, *J* 8.1 Hz, H7-Ind), 7.72 (2H, d, *J* 8.5 Hz, H2,H6-Ar), 8.08 (1H, ddd, *J* 7.8, 1.3, 0.7 Hz, H4-Ind). ¹³C{¹H} NMR (125.7 MHz, DMSO-d₆): δ 164.3 (C=O), 144.8 (C2-Ind), 135.7 (C7a-Ind), 132.4 (C2-Ar), 131.0 (C3-Ar), 130.4 (C1-Ar), 125.9 (C3a-Ind), 122.8 (C6-Ind), 122.5 (C4-Ar), 121.8 (C5-Ind), 121.2 (C4-Ind), 111.0


(C7-Ind), 104.4 (C3-Ind), 50.4 (OCH₃), 44.9 (C5-Alk), 43.2 (C1-Alk), 31.3 (C4-Alk), 28.3 (C2-Alk), 23.3 (C3-Alk). HRMS (MALDI) calcd. for $C_{21}H_{21}ClBrNO_2$ [M+Cs]⁺ 567.9472, found 567.9493.

Methyl 1-(5-chloropentyl)-2-(4-fluorophenyl)-1H-indole-3-carboxylate 11d.



Reddish-brown oil; yield 1.40 g, 75%; R_f (hexane/EtOAc 2:1) 0.56; [Found: C, 67.3; H, 5.9; N, 3.7. C₂₁H₂₁ClFNO₂ requires C, 67.47; H, 5.66; Cl, 9.48; F, 5.08; N, 3.75]. v_{max} (thin film) 3447, 2258, 2130, 1654, 1045, 1026, 997, 828, 767, 651 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta_{\rm H}$ 1.15-1.21 (2H, m, CH₂-Alk3), 1.48-1.58 (4H, m, CH₂-Alk2, CH₂-Alk4), 2.50 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.62 (3H, s, OCH₃), 4.01 (2H, t, *J* 7.5 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 7.2, 7.6, 1.0 Hz, H5-Ind), 7.30 (1H, ddd, *J* 7.6, 8.1, 1.2 Hz, H6-Ind), 7.35 (2H, dd, *J_{HH}* 8.8 Hz, *J_{HF}* 8.8 Hz, H2,H6-Ar), 7.51 (2H, dd, *J_{HH}* 8.8 Hz, *J_{HF}* 3.3 Hz, H3,H5-Ar), 7.64 (1H, br d, *J* 8.1 Hz, H7-Ind), 8.09 (1H, ddd, *J* 7.2, 1.2, 0.7 Hz, H4-Ind). ¹³C{¹H} NMR (125.7 MHz, DMSO-*d*₆): δ 164.3 (C=O), 162.3 (d, ¹*J*_{CF} = 246.1 Hz, C4-Ar), 145.0 (C2-Ind), 135.6 (C7a-Ind), 132.5 (d, ³*J*_{CF} = 8.6 Hz, C2-Ar), 127.5 (d, ⁴*J*_{CF} = 3.2 Hz, C1-Ar), 125.9 (C3a-Ind), 122.7 (C6-Ind), 121.8 (C5-Ind), 121.2 (C4-Ind), 115.0 (d, ²*J*_{CF} = 21.7 Hz, C3-Ar), 111.0 (C7-Ind), 104.4 (C3-Ind), 50.4 (OCH₃), 44.9 (C5-Alk), 43.1 (C1-Alk), 31.2 (C4-Alk), 28.3 (C2-Alk), 23.3 (C3-Alk). ¹⁹F{¹H} NMR (470.5 MHz, DMSO-*d*₆): δ 112.6 (F). HRMS (MALDI) calcd. for C₂₁H₂₁ClFNO₂ [M+Cs]⁺ 506.0294, found 506.0267.


Methyl 1-(5-chloropentyl)-2-(3-bromophenyl)-1H-indole-3-carboxylate 11f.



Yellow oil; yield 1.43 g, 66%; R_f (hexane/EtOAc 2:1) 0.51; [Found: C, 57.9; H, 5.0; N, 3.0. $C_{21}H_{21}BrClNO_2$ requires C, 58.02; H, 4.87; Br, 18.38; Cl, 5.15; N, 3.22]. v_{max} (thin film) 3440, 2256, 2130, 1654, 1044, 1028, 997, 964, 888, 780, 745, 716, 700, 655, 545 cm⁻¹. ¹H NMR (500 MHz,

CDCl₃): $\delta_{\rm H}$ 1.15-1.21 (2H, m, CH₂-Alk3), 1.48-1.54 (2H, m, CH₂-Alk4), 1.54-1.60 (2H, m, CH₂-Alk2), 3.47 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.64 (3H, s, OCH₃), 4.01 (2H, t, *J* 7.5 Hz, CH₂-Alk1), 7.26 (1H, ddd, *J* 8.0, 7.9, 1.1 Hz, H5-Ind), 7.31 (1H, ddd, *J* 8.0, 8.1, 1.4 Hz, H6-Ind), 7.46-7.50 (2H, m, H5,H6-Ar), 7.64 (1H, br d, *J* 8.1 Hz, H7-Ind), 7.68-7.69 (1H, m, H2-Ar), 7.71-7.74 (1H, ddd, *J* 6.9, 2.2, 2.1 Hz, H4-Ar), 8.08 (1H, ddd, *J* 7.9, 1.4, 1.2 Hz, H4-Ind). ¹³C{¹H} NMR (125.7 MHz, DMSO-*d*₆): δ 164.2 (C=O), 144.3 (C2-Ind), 135.7 (C7a-Ind), 133.5 (C1-Ar), 132.8 (C2-Ar), 131.8 (C4-Ar), 130.0 (C5-Ar), 129.4 (C6-Ar), 125.8 (C3a-Ind), 122.9 (C6-Ind), 121.9 (C5-Ind), 121.3 (C4-Ind), 121.1 (C3-Ar), 111.0 (C7-Ind), 104.5 (C3-Ind), 50.5 (OCH₃), 44.9 (C5-Alk), 43.2 (C1-Alk), 31.2 (C4-Alk), 28.3 (C2-Alk), 23.3 (C3-Alk). HRMS (MALDI) calcd. for C₂₁H₂₁ClBrNO₂ [M+Na]⁺ 456.0336;458.0316, found 456.0348;458.0332.


Methyl 1-(5-chloropentyl)-2-(4-nitrophenyl)-1H-indole-3-carboxylate 11g.



Yellow oil; yield 1.80 g, 90%; R_f (hexane/EtOAc 2:1) 0.48; [Found: C, 62.8; H, 5.5; N, 7.2. $C_{21}H_{21}ClN_2O_4$ requires C, 62.92; H, 5.28; Cl, 8.84; N, 6.99]. v_{max} (thin film) 3500, 2861, 1696, 1602, 1047, 1021, 995, 858, 758, 702 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): δ_H 1.15-1.20 (2H, m, CH₂-Alk3), 1.47-1.52 (2H, m, CH₂-Alk4), 1.53-1.58 (2H, m, CH₂-Alk2), 3.46 (2H, t, *J* 6.6 Hz, CH₂-Alk5), 3.63 (3H, s, OCH₃), 4.05 (2H, t, *J* 7.4 Hz, CH₂-Alk1), 7.29 (1H, dd, *J* 7.1, 7.9 Hz, H5-Ind), 7.34 (1H, ddd, *J* 7.1, 8.2, 1.3 Hz, H6-Ind), 7.69 (1H, br d, *J* 8.2 Hz, H7-Ind), 7.79 (2H, d, *J* 8.7 Hz, H2,H6-Ar), 8.10 (1H, br d, *J* 7.9 Hz, H4-Ind), 8.37 (2H, d, *J* 8.7 Hz, H3,H5-Ar). ¹³C{¹H} NMR (150.9 MHz, DMSO-*d*₆): δ 164.2 (C=O), 147.7 (C4-Ar), 143.6 (C2-Ind), 138.1 (C1-Ar), 136.0 (C7a-Ind), 132.0 (C2-Ar), 125.8 (C3a-Ind), 123.2 (C6-Ind), 123.0 (C3-Ar), 122.1 (C5-Ind), 121.3 (C4-Ind), 111.2 (C7-Ind), 104.9 (C3-Ind), 50.6 (OCH₃), 44.9 (C5-Alk), 43.3 (C1-Alk), 31.2 (C4-Alk), 28.3 (C2-Alk), 23.2 (C3-Alk).

Methyl 5-tert-butyl-1-(5-chloropentyl)-2-(4-fluorophenyl)-1H-indole-3-carboxylate 11i.

27



Yellow oil; yield 1.68 g, 78%; R_f (hexane/EtOAc 2:1) 0.58; [Found: C, 69.6; H, 7.0; N, 3.1. $C_{25}H_{29}CIFNO_2$ requires C, 69.84; H, 6.80; Cl, 8.25; F, 4.42; N, 3.26]. v_{max} (thin film) 3593, 3182, 2260, 2131, 1644, 1046, 1024, 983, 830, 772, 742, 721, 669, 649 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ_H 1.15-1.21 (2H, m, CH₂-Alk3), 1.37 (9H, s, (CH₃)₃), 1.48-1.57 (4H, m, CH₂-Alk2, CH₂-Alk4), 3.48 (2H, t, J 6.6 Hz, CH₂-Alk5), 3.59 (3H, s, OCH₃), 3.97 (2H, t, J 7.5 Hz, CH₂-Alk1), 7.34 (2H, dd, J_{HH} 8.9 Hz, J_{HF} 8.9 Hz, H2,H6-Ar), 7.38 (1H, dd, J 8.7, 2.0 Hz, H6-Ind), 7.47 (2H, dd, J_{HH} 8.9 Hz, J_{HF} 3.3 Hz, H3,H5-Ar), 7.53 (1H, dd, J 8.7, 0.4 Hz, H7-Ind), 8.11 (1H, dd, J 2.0, 0.4 Hz, H4-Ind). ¹³C{¹H} NMR (125.7 MHz, DMSO-d₆): δ 164.5 (C=O), 162.3 (d, ¹J_{CF} = 245.8 Hz, C4-Ar), 144.9 (C2-Ind), 144.3 (C5-Ind), 133.9 (C7a-Ind), 132.5 (d, ³J_{CF} = 8.4 Hz, C2-Ar), 127.7 (d, ⁴J_{CF} = 3.2 Hz, C1-Ar), 125.8 (C3a-Ind), 120.8 (C6-Ind), 116.8 (C4-Ind), 115.0 (d, ²J_{CF} = 21.7 Hz, C3-Ar), 110.4 (C7-Ind), 104.3 (C3-Ind), 50.3 (OCH₃), 44.9 (C5-Alk), 43.1 (C1-Alk), 34.4 (C(CH₃)₃), 31.6 (C(<u>CH₃)₃</u>), 31.2 (C4-Alk), 28.3 (C2-Alk), 23.3 (C3-Alk). ¹⁹F{¹H} NMR (470.5 MHz, DMSO-d₆): δ 112.7 (F). HRMS (MALDI) calcd. for $C_{25}H_{29}CIFNO_2$ [M+H]⁺ 430.1944, found 430.1953.

ACKNOWLEDGMENT

This work was supported by the Russian scientific foundation (grant № 14-23-00073).

SUPPLEMENTARY DATA

1D and 2D NMR spectra for all compounds. Supplementary data related to this article can be found at ...

REFERENCES AND NOTES

- (a) Hesse, M. Alkaloids, Nature's Curse or Blessing?, Wiley-VCH, Weinheim, Germany,
 2002, p. 316; (b) Seigler, D. S. Plant Secondary Metabolism, Springer, Berlin, 2001, pp. 628–776.
- (a) Wipf, P.; Spencer, S. R. J. Am. Chem. Soc. 2005, 127, 225–235; (b) Pilli, R. A.; Rosso, G. B.; Ferreira de Oliveira, M. da C. Nat. Prod. Rep. 2010, 27, 1908–1937.
- 3. (a) Stoll, A. Chem. Rev. 1950, 47, 197-218; (b) Eadie, M. J. The Lancet Neurology 2003, 2, 429-434.


- 4. (a) Nagarajan, K. J. Chem. Sci. 2006, 118, 291–309; (b) Nagarajan, K.; Talwalker, P. K.; Shah, R. K.; Mehta, S. R.; Nayak, G. V. Ind. J. Chem. Sect. B: Org. Chem. Incl. Med. Chem., 1985, 24, 98–111.
- 5. Rubin, A. A.; Yen, H. C.; Pfeffer, M. Nature 1967, 216, 578–579.
- 6. Martinez, R.; Clara-Sosa, A.; Ramirez Apan, M. T. Bioorg. Med. Chem. 2007, 15, 3912–3918.
- 7. Morales, C. L.; Pagenkopf, B. L. Org. Lett. 2008, 10, 157–159.
- Ishibashi, H.; Akamatsu, S.; Iriyama, H.; Hanaoka, K.; Tabata, T.; Ikeda, M. Chem. Pharm. Bull. 1994, 42, 271–276.
- 9. (*a*) Hatanaka, N.; Watanabe, N.; Matsumoto, M. *Heterocycles* **1986**, *24*, 3157–3162; (*b*) Remers, W. A.; Roth, R. H.; Gibs, G. J.; Weiss, M. J. J. Org. Chem. **1971**, *36*, 1232–1240.
- For recent reviews of indole synthesis, see (a) Patil, S. A.; Patil, R.; Miller, D. D. Curr. Med. Chem. 2011, 18, 615-637; (b) Cacchi, S.; Fabrizi, G.; Goggiamani, A. Org. Biomol. Chem. 2011, 9, 641-652; (c) Taber, D. F.; Tirunahari, P. K. Tetrahedron 2011, 67, 7195-7210. (d) Song, J. J.; Reeves, J. T.; Fandrick, D. R.; Tan, Z.; Yee, N. K.; Senanayake, C. H. ARKIVOC 2010, 390-449; (e) Palmisano, G.; Penoni, A.; Sisti, M.; Tibiletti, F.; Tollari, S.; Nicholas, K. M. Curr. Org. Chem. 2010, 14, 2409-2441; (f) Patil, S. A.; Patil, R.; Miller, D. D. Curr. Med. Chem. 2009, 16, 2531-2565; (g) Barluenga, J.; Rodriguez, F.; Fananas, F. J. Chem. dAsian J. 2009, 4, 1036e1048; (h) Russel, J. S.; Pelkey, E. T. Prog. Heterocycl. Chem. 2009, 20, 122-151; (i) Kruger, K.; Tillack, A.; Beller, M. Adv. Synth. Catal. 2008, 350, 2153-2167; (j) Humphrey, G. R.; Kuethe, J. T. Chem. Rev. 2006, 106, 2875-2911; (k) Gribble, G. W. Pure Appl. Chem. 2003, 75, 1417-1432; (l) Gribble, G. W. J. Chem. Soc., Perkin Trans. 1 2000, 1045-1075.
- 11. (a) Hamamoto, H.; Mamedov, V. A.; Kitamoto, M.; Hayashi, N.;Tsuboi, S. Tetr. Asymmetry, 2000, 11, 4485 4497; (b) Mamedov, V. A.; Berdnikov, E. A.; Tsuboi, S.; Hamamoto, H.; Komiyama, T.; Gorbunova, E. A.; Gubaidullin, A. T.; Litvinov, I. A. Russ. Chem. Bull., 2006, 55, 1455-1463; (c) Mamedov, V. A.; Nuretdinov, I. A. Bull. Russ. Acad. Sci., Div. Chem. Sci., 1992, 41, 1690-1692; (d) Hirayama, T.; Okaniwa, M.; Imada, T.; Ohashi, A.; Ohori, M.; Iwai, K.; Mori, K.; Kawamoto, T.; Yokota, A.; Tanaka, T.; Ishikawa T. Bioorg. Med. Chem., 2013, 21, 5488-5502; (e) Aissaoui, H.; Boss, C.; Koberstein, R.; Siegrist, R.; Sifferlen, Th.; Trachsel, D. PCT Int. Appl., 2009, WO 2009133522 A1; (f) Mamedov, V. A.; Krokhina, L. V.; II'yasov, A. V. Chem. Heterocyclic Comp., (New York, NY, United States), 1994, 30, 953-956; (g) Saifina, D. F.; Ganieva, V. R.; Mamedov, V. A. Russ. J. Org. Chem., 2009, 45, 1244-1247; (h) Mamedov, V. A.; Zhukova, N. A.; Gubaidullin, A. T.; Beschastnova, T. N.; Rizvanov, I. Kh.; Levin, Ya. A.; Litvinov, I. A. Russ. Chem. Bull., Int. Ed., 2009, 58, 1294-1302.

- Mamedov, V. A.; Beschastnova, T. N.; Zhukova, N. A.; Gubaidullin, A. T.; Isanov, R. A.; Rizvanov, I. Kh. *Tetrahedron Lett.* 2008, 49, 4658–4660.
- (a) Derome, A. E. Modern NMR Techniques for Chemistry Research; Pergamon: Cambridge, U.K, 1988; (b) Atta-ur-Rahman, T. I. One and Two Dimensional NMR Spectroscopy; Elsevier: Amsterdam, 1989, pp. 578.
- 14. (a) Stott, K.; Stonehouse, J.; Keeler, J.; Hwang, T.-L.; Shaka, A. J. J. Am. Chem. Soc.
 1995, 117, 4199-4200; (b) Stott, K.; Keeler, J.; Van, Q. N.; Shaka, A. J. J. Magn. Reson.
 1997, 125, 302-324.

Graphical abstract

Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1enyl)-piperidine and -pyrrolidine with chloropyruvates for the efficient synthesis of substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives

Vakhid A. Mamedov,* Elena A.Hafizova, Anastasiya I. Zamaletdinova, Il'dar Kh. Rizvanov, Alla B. Mirgorodskaya, Lucia Ya. Zakharova, Shamil K. Latypov, Oleg G. Sinyashin



SUPPORTING INFORMATION FOR:

Sequential substitution/ring cleavage/addition reaction of 1-(cyclohex-1-enyl)piperidine and -pyrrolidine with chloropyruvates for the efficient synthesis of substituted 4,5,6,7-tetrahydro-1*H*-indole derivatives

Vakhid A. Mamedov,^{a,b,*} Elena A.Hafizova,^{a,b} Anastasiya I. Zamaletdinova,^{a,b} Il'dar Kh. Rizvanov,^a Alla B. Mirgorodskaya,^{a,b} Lucia Ya. Zakharova,^{a,b} Shamil K. Latypov,^a Oleg G. Sinyashin^{a,b}

> ^aA. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center of the Russian Academy of Sciences, Arbuzov str. 8, 420088 Kazan, Russian Federation

^bKazan National Research Technological University, Karl Marx str. 68, 420015 Kazan, Russian Federation

mamedov@iopc.ru

| Table of Contents | Page |
|---|------|
| General Methods | 9 |
| Figure S1. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 3a in CDCl ₃ at $T = 303$ K. | 10 |
| Figure S2. 2D 1 H- 1 H COSY NMR spectra of 3a in CDCl ₃ at T = 303 K. | 11 |
| Figure S3. 2D ¹ H- ¹³ C HSQC NMR spectra of 3a in CDCl ₃ at T = 303 K. | 12 |
| Figure S4. 2D 1 H- 13 C HMBC NMR spectra of 3a in CDCl ₃ at T = 303 K. | 13 |
| Figure S5. 2D 1 H- 15 N HMBC NMR spectra of 3a in CDCl ₃ at T = 303 K. | 14 |
| Figure S6. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 3b in CDCl ₃ at T = 303 K. | 15 |
| Figure S7. 2D 1 H- 1 H COSY NMR spectra of 3b in CDCl ₃ at T = 303 K. | 16 |
| Figure S8. 2D ¹ H- ¹³ C HSQC NMR spectra of 3b in CDCl ₃ at $T = 303$ K. | 17 |
| Figure S9. 2D ¹ H- ¹³ C HMBC NMR spectra of 3b in CDCl ₃ at T = 303 K. | 18 |
| Figure S10. 1D ¹ H and ¹ H TOCSY NMR spectra of 3b in CDCl ₃ at $T = 303$ K. | 19 |
| Figure S11. 1D ¹ H and ¹ H DPFGROE NMR spectra of 3b in CDCl ₃ at $T = 303$ K. | 20 |
| Figure S12. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 3c in CDCl ₃ at T = 303 K. | 21 |
| Figure S13. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 3d in CDCl ₃ at T = 303 K. | 22 |
| Figure S14. 2D ¹ H- ¹ H COSY NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 23 |
| Figure S15. 2D ¹ H- ¹³ C HSQC NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 24 |
| Figure S16. 2D ¹ H- ¹³ C HMBC NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 25 |
| Figure S17. 2D ¹ H- ¹⁹ F HMBC NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 26 |
| Figure S18. 1D ¹ H and ¹ H TOCSY NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 27 |
| Figure S19. 1D ¹ H and ¹ H DPFGROE NMR spectra of 3d in CDCl ₃ at $T = 303$ K. | 28 |
| Figure S20. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 29 |
| Figure S21. 2D ¹ H- ¹ H COSY NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 30 |

| Figure S22. 2D ¹ H- ¹³ C HSQC NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 31 |
|---|----|
| Figure S23. 2D ¹ H- ¹³ C HMBC NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 32 |
| Figure S24. 1D ¹ H and ¹ H TOCSY NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 33 |
| Figure S25. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 34 |
| Figure S26. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5a in CDCl ₃ at $T = 303$ K. | 35 |
| Figure S27. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5b in CDCl ₃ at $T = 303$ K. | 36 |
| Figure S28. 2D 1 H- 1 H COSY NMR spectra of 5b in CDCl ₃ at T = 303 K. | 37 |
| Figure S29. 2D 1 H- 13 C HSQC NMR spectra of 5b in CDCl ₃ at T = 303 K. | 38 |
| Figure S30. 2D ¹ H- ¹³ C HMBC NMR spectra of 5b in CDCl ₃ at $T = 303$ K. | 39 |
| Figure S31. 2D ¹ H- ¹⁵ N HMBC NMR spectra of 5b in CDCl ₃ at $T = 303$ K. | 40 |
| Figure S32. 1D ¹ H and ¹ H TOCSY NMR spectra of 5b in CDCl ₃ at $T = 303$ K. | 41 |
| Figure S33. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5b in CDCl ₃ at $T = 303$ K. | 42 |
| Figure S34. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5c in CDCl ₃ at $T = 303$ K. | 43 |
| Figure S35. 2D 1 H- 1 H COSY NMR spectra of 5c in CDCl ₃ at T = 303 K. | 44 |
| Figure S36. 2D 1 H- 13 C HSQC NMR spectra of 5c in CDCl ₃ at T = 303 K. | 45 |
| Figure S37. 2D 1 H- 13 C HMBC NMR spectra of 5c in CDCl ₃ at T = 303 K. | 46 |
| Figure S38. 1D ¹ H and ¹ H TOCSY NMR spectra of 5c in CDCl ₃ at $T = 303$ K. | 47 |
| Figure S39. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5c in CDCl ₃ at $T = 303$ K. | 48 |
| Figure S40. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 5d in CDCl ₃ at $T = 303$ K. | 49 |
| Figure S41. 2D ¹ H- ¹ H COSY NMR spectra of 5d in CDCl ₃ at $T = 303$ K. | 50 |
| Figure S42. 2D 1 H- 13 C HSQC NMR spectra of 5d in CDCl ₃ at T = 303 K. | 51 |
| Figure S43. 2D 1 H- 13 C HMBC NMR spectra of 5d in CDCl ₃ at T = 303 K. | 52 |
| Figure S44. 2D 1 H- 19 F HMBC NMR spectra of 5d in CDCl ₃ at T = 303 K. | 53 |
| Figure S45. 1D ¹ H and ¹ H TOCSY NMR spectra of 5d in CDCl ₃ at $T = 303$ K. | 54 |

| Figure S46. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5d in CDCl ₃ at $T = 303$ K. | 55 |
|--|----|
| Figure S47. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5e in CDCl ₃ at $T = 303$ K. | 56 |
| Figure S48. 2D ¹ H- ¹ H COSY NMR spectra of 5e in CDCl ₃ at $T = 303$ K. | 57 |
| Figure S49. 2D 1 H- 13 C HSQC NMR spectra of 5e in CDCl ₃ at T = 303 K. | 58 |
| Figure S50. 2D 1 H- 13 C HMBC NMR spectra of 5e in CDCl ₃ at T = 303 K. | 59 |
| Figure S51. 1D ¹ H and ¹ H TOCSY NMR spectra of 5e in CDCl ₃ at $T = 303$ K. | 60 |
| Figure S52. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5e in CDCl ₃ at $T = 303$ K. | 61 |
| Figure S53. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 62 |
| Figure S54. 2D ¹ H- ¹ H COSY NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 63 |
| Figure S55. 2D ¹ H- ¹³ C HSQC NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 64 |
| Figure S56. 2D ¹ H- ¹³ C HMBC NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 65 |
| Figure S57. 1D ¹ H and ¹ H TOCSY NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 66 |
| Figure S58. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5f in CDCl ₃ at $T = 303$ K. | 67 |
| Figure S59. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5g in CDCl ₃ at T = 303 K. | 68 |
| Figure S60. 2D ¹ H- ¹ H COSY NMR spectra of 5g in CDCl ₃ at $T = 303$ K. | 69 |
| Figure S61. 2D ¹ H- ¹³ C HSQC NMR spectra of 5g in CDCl ₃ at $T = 303$ K. | 70 |
| Figure S62. 2D ¹ H- ¹³ C HMBC NMR spectra of 5g in CDCl ₃ at $T = 303$ K. | 71 |
| Figure S63. 1D ¹ H and ¹ H TOCSY NMR spectra of 5g in CDCl ₃ at $T = 303$ K. | 72 |
| Figure S64. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5g in CDCl ₃ at $T = 303$ K. | 73 |
| Figure S65. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5h in CDCl ₃ at $T = 303$ K. | 74 |
| Figure S66. 2D ¹ H- ¹ H COSY NMR spectra of 5h in CDCl ₃ at $T = 303$ K. | 75 |
| Figure S67. 2D ¹ H- ¹³ C HSQC NMR spectra of 5h in CDCl ₃ at $T = 303$ K. | 76 |
| Figure S68. 2D ¹ H- ¹³ C HMBC NMR spectra of 5h in CDCl ₃ at $T = 303$ K. | 77 |
| Figure S69. 1D ¹ H and ¹ H TOCSY NMR spectra of 5d in CDCl ₃ at $T = 303$ K. | 78 |

| Figure S70. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5h in CDCl ₃ at $T = 303$ K. | 79 |
|---|-----|
| Figure S71. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 5i in CDCl ₃ at $T = 303$ K. | 80 |
| Figure S72. 2D ¹ H- ¹ H COSY NMR spectra of 5i in CDCl ₃ at $T = 303$ K. | 81 |
| Figure S73. 2D 1 H- 13 C HSQC NMR spectra of 5i in CDCl ₃ at T = 303 K. | 82 |
| Figure S74. 2D 1 H- 13 C HMBC NMR spectra of 5i in CDCl ₃ at T = 303 K. | 83 |
| Figure S75. 2D 1 H- 19 F HETCOR NMR spectra of 5i in CDCl ₃ at T = 303 K. | 84 |
| Figure S76. 1D ¹ H and ¹ H TOCSY NMR spectra of 5i in CDCl ₃ at $T = 303$ K. | 85 |
| Figure S77. 1D ¹ H and ¹ H DPFGROE NMR spectra of 5i in CDCl ₃ at $T = 303$ K. | 86 |
| Figure S78. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 5j in CDCl ₃ at $T = 303$ K. | 87 |
| Figure S79. 2D ¹ H- ¹ H COSY NMR spectra of 5j in CDCl ₃ at $T = 303$ K. | 88 |
| Figure S80. 2D 1 H- 13 C HSQC NMR spectra of 5j in CDCl ₃ at T = 303 K. | 89 |
| Figure S81. 2D ¹ H- ¹³ C HMBC NMR spectra of 5j in CDCl ₃ at T = 303 K. | 90 |
| Figure S82. 2D ¹ H- ¹⁵ N HMBC NMR spectra of 5j in CDCl ₃ at T = 303 K. | 91 |
| Figure S83. 2D ¹ H- ¹⁹ F HMBC NMR spectra of 5j in CDCl ₃ at $T = 303$ K. | 92 |
| Figure S84. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5 k in CDCl ₃ at T = 303 K. | 93 |
| Figure S85. 2D ¹ H- ¹ H COSY NMR spectra of 5k in CDCl ₃ at $T = 303$ K. | 94 |
| Figure S86. 2D ¹ H- ¹³ C HSQC NMR spectra of 5k in CDCl ₃ at T = 303 K. | 95 |
| Figure S87. 2D ¹ H- ¹³ C HMBC NMR spectra of 5k in CDCl ₃ at $T = 303$ K. | 96 |
| Figure S88. 2D ¹ H- ¹⁵ N HMBC NMR spectra of 5k in CDCl ₃ at T = 303 K. | 97 |
| Figure S89. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5 I in CDCl ₃ at T = 303 K. | 98 |
| Figure S90. 2D ¹ H- ¹ H COSY NMR spectra of 5l in CDCl ₃ at $T = 303$ K. | 99 |
| Figure S91. 2D 1 H- 13 C HSQC NMR spectra of 5l in CDCl ₃ at T = 303 K. | 100 |
| Figure S92. 2D ¹ H- ¹³ C HMBC NMR spectra of 5 I in CDCl ₃ at $T = 303$ K. | 101 |
| Figure S93. 2D 1 H- 15 N HMBC NMR spectra of 5l in CDCl ₃ at T = 303 K. | 102 |

| Figure S94. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 5m in CDCl ₃ at $T = 303$ K. | 103 | | | | | | | |
|--|-----|--|--|--|--|--|--|--|
| Figure S95. 2D 1 H- 1 H COSY NMR spectra of 5m in CDCl ₃ at T = 303 K. | 104 | | | | | | | |
| Figure S96. 2D ¹ H- ¹³ C HSQC NMR spectra of 5m in CDCl ₃ at T = 303 K. | | | | | | | | |
| Figure S97. 2D ¹ H- ¹³ C HMBC NMR spectra of 5m in CDCl ₃ at $T = 303$ K. | | | | | | | | |
| Figure S98. 2D 1 H- 15 N HMBC NMR spectra of 5m in CDCl ₃ at T = 303 K. | | | | | | | | |
| Figure S99. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 6a in DMSO at T = 303 K. | | | | | | | | |
| Figure S100. 2D 1 H- 1 H COSY NMR spectra of 6a in DMSO at T = 303 K. | | | | | | | | |
| Figure S101. 2D 1 H- 13 C HSQC NMR spectra of 6a in DMSO at T = 303 K. | | | | | | | | |
| Figure S102. 2D 1 H- 13 C HMBC NMR spectra of 6a in DMSO at T = 303 K. | | | | | | | | |
| Figure S103. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 6b in DMSO at $T = 303$ K. | | | | | | | | |
| Figure S104. 2D 1 H- 1 H COSY NMR spectra of 6b in DMSO at T = 303 K. | 113 | | | | | | | |
| Figure S105. 2D 1 H- 13 C HSQC NMR spectra of 6b in DMSO at T = 303 K. | 114 | | | | | | | |
| Figure S106. 2D 1 H- 13 C HMBC NMR spectra of 6b in DMSO at T = 303 K. | 115 | | | | | | | |
| Figure S107. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 7a in DMSO at T = 303 K. | 116 | | | | | | | |
| Figure S108. 2D 1 H- 1 H COSY NMR spectra of 7a in DMSO at T = 303 K. | 117 | | | | | | | |
| Figure S109. 2D 1 H- 13 C HSQC NMR spectra of 7a in DMSO at T = 303 K. | 118 | | | | | | | |
| Figure S110. 2D 1 H- 13 C HMBC NMR spectra of 7a in DMSO at T = 303 K. | 119 | | | | | | | |
| Figure S111. 2D 1 H- 15 N HMBC NMR spectra of 7a in DMSO at T = 303 K. | 120 | | | | | | | |
| Figure S112. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 7g in CDCl ₃ at $T = 303$ K. | 121 | | | | | | | |
| Figure S113. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 10a in DMSO at T = 303 K. | 122 | | | | | | | |
| Figure S114. 2D 1 H- 1 H COSY NMR spectra of 10a in DMSO at T = 303 K. | 123 | | | | | | | |
| Figure S115. 2D 1 H- 13 C HSQC NMR spectra of 10a in DMSO at T = 303 K. | 124 | | | | | | | |
| Figure S116. 2D 1 H- 13 C HMBC NMR spectra of 10a in DMSO at T = 303 K. | 125 | | | | | | | |
| Figure S117. 2D 1 H- 15 N HMBC NMR spectra of 10a in DMSO at T = 303 K. | 126 | | | | | | | |
| | | | | | | | | |


| Figure S118. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 10c in DMSO at $T = 303$ K. | 127 | | | | | | | |
|--|-----|--|--|--|--|--|--|--|
| Figure S119. 2D ¹ H- ¹ H COSY NMR spectra of 10c in DMSO at $T = 303$ K. | 128 | | | | | | | |
| Figure S120. 2D 1 H- 13 C HSQC NMR spectra of 10c in DMSO at T = 303 K. | | | | | | | | |
| Figure S121. 2D 1 H- 13 C HMBC NMR spectra of 10c in DMSO at T = 303 K. | | | | | | | | |
| Figure S122. 1D ¹ H and ¹ H TOCSY NMR spectra of 10c in DMSO at $T = 303$ K. | | | | | | | | |
| Figure S123. 1D ¹ H and ¹ H DPFGROE NMR spectra of 10c in DMSO at $T = 303$ K. | | | | | | | | |
| Figure S124. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 10d in DMSO at T = 303 K. | | | | | | | | |
| Figure S125. 2D 1 H- 1 H COSY NMR spectra of 10d in DMSO at T = 303 K. | | | | | | | | |
| Figure S126. 2D ¹ H- ¹³ C HSQC NMR spectra of 10d in DMSO at $T = 303$ K. | 135 | | | | | | | |
| Figure S127. 2D ¹ H- ¹³ C HMBC NMR spectra of 10d in DMSO at T = 303 K. | 136 | | | | | | | |
| Figure S128. 2D ¹ H- ¹⁹ F HMBC NMR spectra of 10d in DMSO at T = 303 K. | 137 | | | | | | | |
| Figure S129. 1D ¹ H and ¹ H DPFGROE NMR spectra of 10d in DMSO at $T = 303$ K. | 138 | | | | | | | |
| Figure S130. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 10g in DMSO at T = 303 K. | 139 | | | | | | | |
| Figure S131. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 11b in DMSO at $T = 303$ K. | 140 | | | | | | | |
| Figure S132. 2D ¹ H- ¹ H COSY NMR spectra of 11b in DMSO at $T = 303$ K. | 141 | | | | | | | |
| Figure S133. 2D 1 H- 13 C HSQC NMR spectra of 11b in DMSO at T = 303 K. | 142 | | | | | | | |
| Figure S134. 2D 1 H- 13 C HMBC NMR spectra of 11b in DMSO at T = 303 K. | 143 | | | | | | | |
| Figure S135. 1D ¹ H and ¹ H DPFGROE NMR spectra of 11b in DMSO at $T = 303$ K. | 144 | | | | | | | |
| Figure S136. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 11c in DMSO at T = 303 K. | 145 | | | | | | | |
| Figure S137. 2D ¹ H- ¹ H COSY NMR spectra of 11c in DMSO at $T = 303$ K. | 146 | | | | | | | |
| Figure S138. 2D 1 H- 13 C HSQC NMR spectra of 11c in DMSO at T = 303 K. | 147 | | | | | | | |
| Figure S139. 2D 1 H- 13 C HMBC NMR spectra of 11c in DMSO at T = 303 K. | 148 | | | | | | | |
| Figure S140. 1D ¹ H and ¹ H TOCSY NMR spectra of 11c in DMSO at $T = 303$ K. | 149 | | | | | | | |
| Figure S141. 1D ¹ H and ¹ H DPFGROE NMR spectra of 11c in DMSO at $T = 303$ K. | 150 | | | | | | | |
| | | | | | | | | |

| Figure S142. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 11d in DMSO at $T = 303$ K. | 151 | | | | | | |
|--|-----|--|--|--|--|--|--|
| Figure S143. 2D 1 H- 1 H COSY NMR spectra of 11d in DMSO at T = 303 K. | 152 | | | | | | |
| Figure S144. 2D 1 H- 13 C HSQC NMR spectra of 11d in DMSO at T = 303 K. | | | | | | | |
| Figure S145. 2D 1 H- 13 C HMBC NMR spectra of 11d in DMSO at T = 303 K. | | | | | | | |
| Figure S146. 1D ¹ H and ¹ H TOCSY NMR spectra of 11d in DMSO at $T = 303$ K. | | | | | | | |
| Figure S147. 1D ¹ H and ¹ H DPFGROE NMR spectra of 11d in DMSO at $T = 303$ K. | | | | | | | |
| Figure S148. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 11f in DMSO at T = 303 K. | | | | | | | |
| Figure S149. 2D 1 H- 1 H COSY NMR spectra of 11f in DMSO at T = 303 K. | 158 | | | | | | |
| Figure S150. 2D 1 H- 13 C HSQC NMR spectra of 11f in DMSO at T = 303 K. | 159 | | | | | | |
| Figure S151. 2D 1 H- 13 C HMBC NMR spectra of 11f in DMSO at T = 303 K. | 160 | | | | | | |
| Figure S152. 1D ¹ H and ¹ H TOCSY NMR spectra of 11f in DMSO at $T = 303$ K. | 161 | | | | | | |
| Figure S153. 1D ¹ H and ¹ H DPFGROE NMR spectra of 11f in DMSO at T = 303 K. | | | | | | | |
| Figure S154. 1D ¹ H, ¹³ C DEPT and ¹³ C{ ¹ H} NMR spectra of 11g in DMSO at $T = 303$ K. | 163 | | | | | | |
| Figure S155. 2D 1 H- 1 H COSY NMR spectra of 11g in DMSO at T = 303 K. | 164 | | | | | | |
| Figure S156. 2D 1 H- 13 C HSQC NMR spectra of 11g in DMSO at T = 303 K. | 165 | | | | | | |
| Figure S157. 2D 1 H- 13 C HMBC NMR spectra of 11g in DMSO at T = 303 K. | 166 | | | | | | |
| Figure S158. 1D ¹ H, ¹³ C DEPT, ¹³ C{ ¹ H} and ¹⁹ F{ ¹ H} NMR spectra of 11i in DMSO at T = 303 K. | 167 | | | | | | |
| Figure S159. 2D 1 H- 1 H COSY NMR spectra of 11i in DMSO at T = 303 K. | 168 | | | | | | |
| Figure S160. 2D 1 H- 13 C HSQC NMR spectra of 11i in DMSO at T = 303 K. | 169 | | | | | | |
| Figure S161. 2D 1 H- 13 C HMBC NMR spectra of 11i in DMSO at T = 303 K. | 170 | | | | | | |
| Figure S162. 2D 1 H- 15 F HMBC NMR spectra of 11i in DMSO at T = 303 K. | 171 | | | | | | |
| Figure S163. 1D ¹ H and ¹ H DPFGROE NMR spectra of 11i in DMSO at $T = 303$ K. | 172 | | | | | | |
| | | | | | | | |

General Methods

All NMR experiments were performed with a 600, 500 and 400 MHz (600, 500 and 400 MHz for ¹H NMR; 100 MHz for ¹³C NMR; 60 MHz for ¹⁵N NMR, respectively) spectrometers equipped with a 5 mm diameter gradient inverse broad band probehead and a pulsed gradient unit capable of producing magnetic field pulse gradients in the z-direction of 53.5 G·cm⁻¹. NMR experiments were carried out at 303 K. DPFGROE and TOCSY spectra were obtained using a Hermite-shaped pulse for selective excitation. Chemical shifts (δ in ppm) are referenced to the solvents (CDCl₃ (δ = 7.27 ppm for ¹H and 77.0 ppm for ¹³C NMR) or DMSO-*d*₆ (δ = 2.49 ppm for ¹H and 39.5 ppm for ¹³C NMR)), to external CD₃NO₂ (380.2 ppm) for ¹⁵N NMR spectra (conversion factor to NH₃: -380.2 ppm) and to external C₆F₆ (-164.9 ppm) for ¹⁹F NMR spectra.

CEP HANG






Figure S1. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **3a** in CDCl₃ at T = 303 K.




Figure S2. 2D 1 H- 1 H COSY NMR spectra of **3a** in CDCl₃ at T = 303 K.




Figure S3. 2D 1 H- 13 C HSQC NMR spectra of **3a** in CDCl₃ at T = 303 K.




Figure S4. 2D 1 H- 13 C HMBC NMR spectra of **3a** in CDCl₃ at T = 303 K.




Figure S5. 2D 1 H- 15 N HMBC NMR spectra of **3a** in CDCl₃ at T = 303 K.




Figure S6. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S7. 2D 1 H- 1 H COSY NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S8. 2D 1 H- 13 C HSQC NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S9. 2D 1 H- 13 C HMBC NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S10. 1D ¹H and ¹H TOCSY NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S11. 1D ¹H and ¹H DPFGROE NMR spectra of **3b** in CDCl₃ at T = 303 K.




Figure S12. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **3c** in CDCl₃ at T = 303 K.




Figure S13. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S14. 2D 1 H- 1 H COSY NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S15. 2D 1 H- 13 C HSQC NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S16. 2D 1 H- 13 C HMBC NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S17. 2D 1 H- 19 F HMBC NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S18. 1D ¹H and ¹H TOCSY NMR spectra of **3d** in CDCl₃ at T = 303 K.






Figure S19. 1D ¹H and ¹H DPFGROE NMR spectra of **3d** in CDCl₃ at T = 303 K.




Figure S20. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5a** in CDCl₃ at T = 303 K.




Figure S21. 2D 1 H- 1 H COSY NMR spectra of **5a** in CDCl₃ at T = 303 K.




Figure S22. 2D 1 H- 13 C HSQC NMR spectra of **5a** in CDCl₃ at T = 303 K.




Figure S23. 2D 1 H- 13 C HMBC NMR spectra of **5a** in CDCl₃ at T = 303 K.

| | | | | | | | | M | | | | | Λ |
|-----|-----|-----|-----|-----|-----|-----|-----|---------------|-----|-----|-----|----------|-----|
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |
| | | | | | | | | | | | M | | |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |
| | | | | | | | | | | | M_ | | |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppn |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | \wedge | Μ |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |
| | | | | | | | , | Λ_{-} | | | | _m/_ | Λ |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |
| _M_ | | | | | | | | | | | | | |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |
| | | | | | | | | ML | | | | | л |
| 7.5 | 7.0 | 6.5 | 6.0 | 5.5 | 5.0 | 4.5 | 4.0 | 3.5 | 3.0 | 2.5 | 2.0 | 1.5 | ppm |

Figure S24. 1D ¹H and ¹H TOCSY NMR spectra of **5a** in $CDCl_3$ at T = 303 K.




Figure S25. 1D ¹H and ¹H DPFGROE NMR spectra of **5a** in CDCl₃ at T = 303 K.




Figure S26. 1D ¹H and ¹H DPFGROE NMR spectra of **5a** in CDCl₃ at T = 303 K.




Figure S27. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S28. 2D 1 H- 1 H COSY NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S29. 2D 1 H- 13 C HSQC NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S30. 2D 1 H- 13 C HMBC NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S31. 2D 1 H- 15 N HMBC NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S32. 1D ¹H and ¹H TOCSY NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S33. 1D ¹H and ¹H DPFGROE NMR spectra of **5b** in CDCl₃ at T = 303 K.




Figure S34. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5c** in CDCl₃ at T = 303 K.




Figure S35. 2D 1 H- 1 H COSY NMR spectra of **5c** in CDCl₃ at T = 303 K.




Figure S36. 2D 1 H- 13 C HSQC NMR spectra of **5c** in CDCl₃ at T = 303 K.




Figure S37. 2D 1 H- 13 C HMBC NMR spectra of **5c** in CDCl₃ at T = 303 K.




Figure S38. 1D ¹H and ¹H TOCSY NMR spectra of **5c** in CDCl₃ at T = 303 K.




Figure S39. 1D ¹H and ¹H DPFGROE NMR spectra of **5c** in CDCl₃ at T = 303 K.

ACCEPTED MANUSCRIPT




Figure S40. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S41. 2D 1 H- 1 H COSY NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S42. 2D 1 H- 13 C HSQC NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S43. 2D 1 H- 13 C HMBC NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S44. 2D 1 H- 19 F HMBC NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S45. 1D ¹H and ¹H TOCSY NMR spectra of **5d** in CDCl₃ at T = 303 K.

ACCEPTED MANUSCRIPT




Figure S46. 1D ¹H and ¹H DPFGROE NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S47. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S48. 2D 1 H- 1 H COSY NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S49. 2D 1 H- 13 C HSQC NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S50. 2D 1 H- 13 C HMBC NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S51. 1D ¹H and ¹H TOCSY NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S52. 1D ¹H and ¹H DPFGROE NMR spectra of **5e** in CDCl₃ at T = 303 K.




Figure S53. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S54. 2D 1 H- 1 H COSY NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S55. 2D 1 H- 13 C HSQC NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S56. 2D 1 H- 13 C HMBC NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S57. 1D ¹H and ¹H TOCSY NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S58. 1D ¹H and ¹H DPFGROE NMR spectra of **5f** in CDCl₃ at T = 303 K.




Figure S59. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5g** in CDCl₃ at T = 303 K.




Figure S60. 2D 1 H- 1 H COSY NMR spectra of **5g** in CDCl₃ at T = 303 K.




Figure S61. 2D 1 H- 13 C HSQC NMR spectra of **5g** in CDCl₃ at T = 303 K.




Figure S62. 2D 1 H- 13 C HMBC NMR spectra of **5g** in CDCl₃ at T = 303 K.




Figure S63. 1D ¹H and ¹H TOCSY NMR spectra of **5g** in CDCl₃ at T = 303 K.




Figure S64. 1D ¹H and ¹H DPFGROE NMR spectra of 5g in CDCl₃ at T = 303 K.




Figure S65. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5h** in CDCl₃ at T = 303 K.




Figure S66. 2D 1 H- 1 H COSY NMR spectra of **5h** in CDCl₃ at T = 303 K.




Figure S67. 2D 1 H- 13 C HSQC NMR spectra of **5h** in CDCl₃ at T = 303 K.




Figure S68. 2D 1 H- 13 C HMBC NMR spectra of **5h** in CDCl₃ at T = 303 K.




Figure S69. 1D ¹H and ¹H TOCSY NMR spectra of **5d** in CDCl₃ at T = 303 K.




Figure S70. 1D ¹H and ¹H DPFGROE NMR spectra of **5h** in CDCl₃ at T = 303 K.




Figure S71. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S72. 2D 1 H- 1 H COSY NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S73. 2D 1 H- 13 C HSQC NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S74. 2D 1 H- 13 C HMBC NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S75. 2D 1 H- 19 F HETCOR NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S76. 1D ¹H and ¹H TOCSY NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S77. 1D ¹H and ¹H DPFGROE NMR spectra of **5i** in CDCl₃ at T = 303 K.




Figure S78. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S79. 2D 1 H- 1 H COSY NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S80. 2D 1 H- 13 C HSQC NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S81. 2D 1 H- 13 C HMBC NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S82. 2D 1 H- 15 N HMBC NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S83. 2D 1 H- 19 F HMBC NMR spectra of **5j** in CDCl₃ at T = 303 K.




Figure S84. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5**k in CDCl₃ at T = 303 K.




Figure S85. 2D 1 H- 1 H COSY NMR spectra of **5k** in CDCl₃ at T = 303 K.




Figure S86. 2D 1 H- 13 C HSQC NMR spectra of **5k** in CDCl₃ at T = 303 K.




Figure S87. 2D 1 H- 13 C HMBC NMR spectra of **5k** in CDCl₃ at T = 303 K.




Figure S88. 2D 1 H- 15 N HMBC NMR spectra of **5k** in CDCl₃ at T = 303 K.




Figure S89. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of 5l in CDCl₃ at T = 303 K.




Figure S90. 2D 1 H- 1 H COSY NMR spectra of **5l** in CDCl₃ at T = 303 K.




Figure S91. 2D 1 H- 13 C HSQC NMR spectra of **5l** in CDCl₃ at T = 303 K.




Figure S92. 2D 1 H- 13 C HMBC NMR spectra of **5l** in CDCl₃ at T = 303 K.




Figure S93. 2D 1 H- 15 N HMBC NMR spectra of **5l** in CDCl₃ at T = 303 K.




Figure S94. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **5m** in CDCl₃ at T = 303 K.




Figure S95. 2D 1 H- 1 H COSY NMR spectra of **5m** in CDCl₃ at T = 303 K.




Figure S96. 2D 1 H- 13 C HSQC NMR spectra of **5m** in CDCl₃ at T = 303 K.




Figure S97. 2D 1 H- 13 C HMBC NMR spectra of **5m** in CDCl₃ at T = 303 K.




Figure S98. 2D 1 H- 15 N HMBC NMR spectra of **5m** in CDCl₃ at T = 303 K.




Figure S99. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **6a** in DMSO at T = 303 K.




Figure S100. 2D 1 H- 1 H COSY NMR spectra of **6a** in DMSO at T = 303 K.




Figure S101. 2D 1 H- 13 C HSQC NMR spectra of **6a** in DMSO at T = 303 K.




Figure S102. 2D 1 H- 13 C HMBC NMR spectra of **6a** in DMSO at T = 303 K.




Figure S103. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **6b** in DMSO at T = 303 K.




Figure S104. 2D 1 H- 1 H COSY NMR spectra of **6b** in DMSO at T = 303 K.




Figure S105. 2D 1 H- 13 C HSQC NMR spectra of **6b** in DMSO at T = 303 K.




Figure S106. 2D 1 H- 13 C HMBC NMR spectra of **6b** in DMSO at T = 303 K.




Figure S107. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **7a** in DMSO at T = 303 K.




Figure S108. 2D 1 H- 1 H COSY NMR spectra of **7a** in DMSO at T = 303 K.




Figure S109. 2D 1 H- 13 C HSQC NMR spectra of **7a** in DMSO at T = 303 K.




Figure S110. 2D 1 H- 13 C HMBC NMR spectra of **7a** in DMSO at T = 303 K.




Figure S111. 2D ¹H-¹⁵N HMBC NMR spectra of **7a** in DMSO at T = 303 K.




Figure S112. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **7g** in CDCl₃ at T = 303 K.




Figure S113. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **10a** in DMSO at T = 303 K.




Figure S114. 2D 1 H- 1 H COSY NMR spectra of **10a** in DMSO at T = 303 K.




Figure S115. 2D 1 H- 13 C HSQC NMR spectra of **10a** in DMSO at T = 303 K.




Figure S116. 2D 1 H- 13 C HMBC NMR spectra of 10a in DMSO at T = 303 K.




Figure S117. 2D 1 H- 15 N HMBC NMR spectra of **10a** in DMSO at T = 303 K.




Figure S118. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **10c** in DMSO at T = 303 K.




Figure S119. 2D 1 H- 1 H COSY NMR spectra of **10c** in DMSO at T = 303 K.




Figure S120. 2D 1 H- 13 C HSQC NMR spectra of **10c** in DMSO at T = 303 K.




Figure S121. 2D 1 H- 13 C HMBC NMR spectra of **10c** in DMSO at T = 303 K.




Figure S122. 1D ¹H and ¹H TOCSY NMR spectra of **10c** in DMSO at T = 303 K.




Figure S123. 1D ¹H and ¹H DPFGROE NMR spectra of **10c** in DMSO at T = 303 K.




Figure S124. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **10d** in DMSO at T = 303 K.




Figure S125. 2D 1 H- 1 H COSY NMR spectra of **10d** in DMSO at T = 303 K.




Figure S126. 2D 1 H- 13 C HSQC NMR spectra of **10d** in DMSO at T = 303 K.




Figure S127. 2D 1 H- 13 C HMBC NMR spectra of **10d** in DMSO at T = 303 K.




Figure S128. 2D 1 H- 19 F HMBC NMR spectra of **10d** in DMSO at T = 303 K.






Figure S129. 1D ¹H and ¹H DPFGROE NMR spectra of **10d** in DMSO at T = 303 K.




Figure S130. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **10g** in DMSO at T = 303 K.




Figure S131. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **11b** in DMSO at T = 303 K.




Figure S132. 2D 1 H- 1 H COSY NMR spectra of **11b** in DMSO at T = 303 K.




Figure S133. 2D 1 H- 13 C HSQC NMR spectra of **11b** in DMSO at T = 303 K.




Figure S134. 2D 1 H- 13 C HMBC NMR spectra of **11b** in DMSO at T = 303 K.




Figure S135. 1D ¹H and ¹H DPFGROE NMR spectra of **11b** in DMSO at T = 303 K.




Figure S136. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of 11c in DMSO at T = 303 K.




Figure S137. 2D 1 H- 1 H COSY NMR spectra of **11c** in DMSO at T = 303 K.




Figure S138. 2D 1 H- 13 C HSQC NMR spectra of **11c** in DMSO at T = 303 K.




Figure S139. 2D 1 H- 13 C HMBC NMR spectra of **11c** in DMSO at T = 303 K.




Figure S140. 1D ¹H and ¹H TOCSY NMR spectra of **11c** in DMSO at T = 303 K.




Figure S141. 1D ¹H and ¹H DPFGROE NMR spectra of **11c** in DMSO at T = 303 K.

ACCEPTED MANUSCRIPT




Figure S142. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **11d** in DMSO at T = 303 K.




Figure S143. 2D 1 H- 1 H COSY NMR spectra of **11d** in DMSO at T = 303 K.




Figure S144. 2D 1 H- 13 C HSQC NMR spectra of **11d** in DMSO at T = 303 K.




Figure S145. 2D 1 H- 13 C HMBC NMR spectra of **11d** in DMSO at T = 303 K.

. 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.0 2.5 2.0 8.0 3.5 1.5 ppr 7.5 7.0 8.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppr · | 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 ppr 8.0 · | 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 8.0 1.5 pp

Figure S146. 1D ¹H and ¹H TOCSY NMR spectra of **11d** in DMSO at T = 303 K.




Figure S147. 1D ¹H and ¹H DPFGROE NMR spectra of **11d** in DMSO at T = 303 K.

ACCEPTED MANUSCRIPT




Figure S148. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **11f** in DMSO at T = 303 K.




Figure S149. 2D 1 H- 1 H COSY NMR spectra of **11f** in DMSO at T = 303 K.




Figure S150. 2D 1 H- 13 C HSQC NMR spectra of **11f** in DMSO at T = 303 K.




Figure S151. 2D 1 H $^{-13}$ C HMBC NMR spectra of **11f** in DMSO at T = 303 K.




Figure S152. 1D ¹H and ¹H TOCSY NMR spectra of **11f** in DMSO at T = 303 K.




Figure S153. 1D ¹H and ¹H DPFGROE NMR spectra of **11f** in DMSO at T = 303 K.




Figure S154. 1D ¹H, ¹³C DEPT and ¹³C{¹H} NMR spectra of **11g** in DMSO at T = 303 K.




Figure S155. 2D 1 H- 1 H COSY NMR spectra of **11g** in DMSO at T = 303 K.




Figure S156. 2D 1 H- 13 C HSQC NMR spectra of **11g** in DMSO at T = 303 K.




Figure S157. 2D 1 H- 13 C HMBC NMR spectra of **11g** in DMSO at T = 303 K.




Figure S158. 1D ¹H, ¹³C DEPT, ¹³C{¹H} and ¹⁹F{¹H} NMR spectra of **11i** in DMSO at T = 303 K.




Figure S159. 2D 1 H- 1 H COSY NMR spectra of **11i** in DMSO at T = 303 K.




Figure S160. 2D 1 H- 13 C HSQC NMR spectra of 11i in DMSO at T = 303 K.




Figure S161. 2D 1 H- 13 C HMBC NMR spectra of **11i** in DMSO at T = 303 K.




Figure S162. 2D 1 H- 15 F HMBC NMR spectra of **11i** in DMSO at T = 303 K.

ACCEPTED MANUSCRIP




Figure S163. 1D ¹H and ¹H DPFGROE NMR spectra of **11i** in DMSO at T = 303 K.